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Vaccine efficacy can be established through the estimation of several numerical 
measures. A common measure of efficacy for vaccines, especially those designed to prevent a 
given disease, is the prevented fraction.  Unfortunately, the prevented fraction can be used only 
when the outcome is dichotomous. It is worth noting that some useful vaccines reduce the 
severity of the targeted disease rather than entirely prevent its occurrence. The concept of the 
mitigated fraction was introduced in veterinary medicine to quantify the reduction in the severity 
of disease occurring in vaccinated animals as compared to non-vaccinated animals. The USDA’s 
Center for Veterinary Biologics (CVB) recommends a form of the mitigated fraction proposed 
by Siev (2005) which can be easily calculated when the disease severity can be graded by some 
continuous measure or by some discrete assessment resulting in unambiguous ranks. Current 
CVB guidance suggests that the mitigated fraction be estimated non-parametrically via the use of 
the Wilcoxon rank sum statistics. 
A survey of recent literature indicates a growing interest in measures of efficacy when the 
outcome variable is ordinal, especially when observations are clustered or measured 
longitudinally. Here, a parametric approach assuming a generalized linear mixed model 
(GLMM) with latent variable is developed for data collected in a completely randomized design 
(CRD) or a randomized complete block design (RCBD) and is then evaluated through 
simulation. Results show this parametric approach works well for both the CRD and RCBD.  
The GLMM approach can be extended to studies where more than two treatments are compared 
whereas the method of Siev (2005) can handle only two treatment groups (vaccinated and non-
vaccinated). Furthermore, a Bayesian statistical approach has been briefly explored to estimate 
the mitigated fraction from an ordinal response observed in a completely randomized design. 
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Chapter 1 - Introduction 
A vaccine is generally a fluid containing weakened or dead microorganisms known to 
cause disease. A vaccine is typically applied to an individual subject by injection but may be 
taken orally or via a nasal mist. The main purpose of vaccination is to make the immune system 
in vaccinated subjects ready in advance to prevent or cure an infection. Vaccination (a way of 
getting a vaccine) is one of the most remarkable health benefits and became popular with the 
great achievement of a smallpox vaccine and now with the current pandemic of Covid-19. The 
primary focus has been on how well the vaccine protects the vaccinated subjects compared with 
non-vaccinated subjects. Clinical trials are conducted to evaluate vaccine efficacy (𝑉𝐸).  The 
“efficacy” of a vaccine refers to its ability to either prevent infection or reduce the incidence 
and/or severity of the associated disease in the target population (Mehrota, 2006). 
 
1.1 Relative risk and vaccine efficacy 
Here some of the technical terms and definitions in vaccine fields are briefly discussed. 
Suppose a subject is selected at random from a population and let A and 𝐵 denote two events. 
Specifically, let 𝐴 be the event that the subject is vaccinated. Then the complement of 𝐴, denoted 
by ?̅?, is the event that the subject is not vaccinated.  Let 𝐵 be the event that subject has a certain 
health-related characteristic, e.g., the subject develops a disease such as Covid-19. Now let 𝑃(𝐵|𝐴) 
denote the risk of the occurrence of 𝐵 given 𝐴, i.e. the risk that a vaccinated subject develops 
Covid-19.  Then 𝑃(𝐵|?̅?) denotes the risk of the occurrence of 𝐵 given ?̅?, i.e. the risk that an 
unvaccinated subject develops Covid-19.  The two groups of subjects defined by 𝐴 and ?̅?, e.g. the 
vaccinated and unvaccinated subjects, are often compared through the relative risk (𝑅𝑅) which is 






Halloran and Longini (1997) define vaccine efficacy (𝑉𝐸) to be a measure based on the relative 
risk of a particular outcome of the form 𝑉𝐸 =  1 − 𝑅𝑅. 
Following Centers for Disease Control and Prevention (CDC), it can clearly be 
understood that 𝑉𝐸 is measured by calculating the risk of disease among vaccinated and 
unvaccinated subjects and determining the percentage reduction in risk of disease among 
vaccinated subjects relative to unvaccinated subjects. The greater the percentage reduction of 
disease in the vaccinated group, the greater the vaccine efficacy (CDC, 2012). A vaccine is 100% 
efficacious if 𝑉𝐸 =  1. 
 
1.2 Prevented Fraction (𝑷𝑭) 
Medical interventions are intended to either reduce or prevent disease. Statistical tools are 
used to estimate the effect of an intervention on disease reduction or prevention. As Siev (2005) 
stated, when a medical intervention is intended to prevent a dichotomous outcome (e.g., clinical 
signs of disease are observed on a subject as presence or absence), an estimator known as the 
prevented fraction (𝑃𝐹) is commonly used to measure the effect of the intervention on 
preventing disease. As the usual estimator for efficacy of vaccine, 𝑃𝐹 is often simply termed 
vaccine efficacy (𝑉𝐸) in vaccine studies (Siev ,2005). It is to be clearly understood that the 
prevented fraction (𝑃𝐹) is commonly used for interventions other than vaccines whereas vaccine 
efficacy (𝑉𝐸) is used in vaccine studies. As discussed in the Halloran et al. (1997), 𝑉𝐸 may be 




According to the Centers for Disease Control and Prevention (CDC), 𝑃𝐹 measures the 
proportionate reduction in cases (disease occurrences) among the vaccinated group (CDC, 2012).  
 
Let us consider some examples based on prevented fraction (𝑃𝐹): 
Ex 1: Pfizer-BNT162b2 mRNA Covid-19 vaccine 
Pollack et al. (2020) discussed a clinical trial for the safety and efficacy of the BNT162b2 
mRNA Covid-19 vaccine. In a clinical trial, a total of 43,548 participants underwent 
randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with 
placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among 
participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo.  
Letting 𝑛1 be the number of people in the vaccinated group and 𝑛2 be the number of people in 
the control group, then 𝑛1  =  21,720 and 𝑛2  =  21,728. 
Similarly, letting 𝑥1 be the number of people infected with the virus in the vaccinated group and 
𝑥2 be the number of people infected with the virus in the control group, we have 𝑥1  =  8 and 
𝑥2  =  162. 
Following the convention about relative risk (𝑅𝑅) discussed in Section 1.1, let 𝐴 be the 
vaccinated group and ?̅? be the unvaccinated group where B is defined to be the event the subject 
develops Covid-19 7 or more days after the second dose. The corresponding estimated risks are 
then defined to be 
𝑃(𝐵|𝐴) =  𝑥1 / 𝑛1 = 8/21,720   =  0.000368 
  𝑃(𝐵|?̅?) =  𝑥2 / 𝑛2 = 162/21,728 =  0.007456 







𝑃𝐹 of 95.1% indicates a 95.1% reduction in disease occurrence among the vaccinated group. 
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So, the vaccinated group experienced 95.1% fewer disease cases than they would have if they 
had not been vaccinated. 
Ex 2: Outbreak of varicella (chickenpox) in Oregon in 2002 
Tugwell et al. (2004) investigated a chickenpox outbreak that started in an Oregon 
elementary school in October 2001, after public schools began phasing in a varicella vaccination 
requirement for enrollment. In that chickenpox outbreak study, varicella was diagnosed in 18 of 
152 vaccinated children compared with 3 of 7 unvaccinated children. 
Here  𝑛1  =  152, 𝑛2  =  7, 𝑥1  =  18, and 𝑥2  =  3 
Using the above formula, 𝑃𝐹 will be equal 0.72. So, the vaccinated group experienced 72% 
fewer varicella cases than they would have if they had not been vaccinated. 
 
1.3 Mitigated Fraction 
Prevented fraction (𝑃𝐹) is used in studies where the response observed on subjects is a 
dichotomous outcome, e.g., clinical signs of disease are observed in a subject as presence or 
absence. Recent studies indicate a growing interest in the vaccine’s ability to reduce the severity 
of the targeted disease rather than preventing it entirely.  The concept of the mitigated fraction 
was introduced in veterinary medicine to quantify the reduction in the severity of disease 
occurring in vaccinated animals as compared to non-vaccinated animals. The USDA’s Center for 
Veterinary Biologics (CVB) recommends a form of the mitigated fraction proposed by Siev 
(2005) which can be calculated when the disease severity is graded by some continuous measure 
or by some discrete assessment resulting in unambiguous ranks. Siev (2005) outlined and 
structured the formulation of the mitigated fraction in a non-parametric approach based on 
Wilcoxon rank sum statistics. A motivated example was given in Siev (2005) describing a study 
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to determine the efficacy of a vaccine in terms of finding the mitigated fraction for swine 
respiratory disease with two treatment groups, one group of pigs treated with the vaccine and 
other group of pigs treated with a placebo (i.e. the control group).  
1.4 The motivated example for mitigated fraction from Siev (2005) 
Siev (2005) describes a study to determine the efficacy of a vaccine for swine respiratory 
disease with two treatment groups, pigs treated with the vaccine and pigs treated with a placebo 
(i.e. the control group). In this study all the pigs were exposed to the pathogen and sacrificed. A 
postmortem examination of each pig’s lungs was conducted to measure the extent of gross 
lesions. Two observers independently sketched on a grid of the dorsal and ventral surfaces of 
each of the seven lung lobes. The fraction of each lobe was taken as the average of the two 
surfaces over the two observers. The lobe fractions were then weighted and summed to arrive at 
the fraction of the lungs affected by gross lesions. This response variable is clearly continuous. 
Siev (2005) pointed out a possible analysis would be to convert the fraction of gross lung lesions 
to a dichotomous response, say unaffected (i.e. 0% lesions) and affected (greater than 0%). This 
variable could then be analyzed in terms of the prevented fraction (𝑃𝐹). As Siev (2005) 
mentioned, important information is lost when considering only presence/absence since it 
ignores the severity of the affected individuals. However, Siev (2005) mentioned that if disease 
severity can be graded by some continuous measure or perhaps a discrete assessment that results 






1.5 Mathematical formulation for mitigated Fraction 
The mitigated fraction (𝑀𝐹) is defined as the relative increase in the probability that a 
vaccinate’s disease will be less severe than a non-vaccinate’s disease (Siev, 2005). Let 𝑌 
represent a response variable measured on an individual denoting the severity of its disease. 
Without a loss of generality, assume that larger values of 𝑌 indicate greater severity.  Now let 𝑌1 
be the observed value of this variable for an individual randomly selected from the control 
(placebo) group and let 𝑌2 be the response for a randomly selected individual from the vaccine 
group.  
Mathematically, that mitigated fraction can be expressed as: 
𝑀𝐹 = 𝑃(𝑌1 > 𝑌2) − 𝑃(𝑌2 > 𝑌1). 
The mitigated fraction can be reformulated in the following way. A measure that summarizes the 
relative effect size of 𝑌1 and 𝑌2 is 
𝑇(𝑌1, 𝑌2) = 𝑃(𝑌1 > 𝑌2) +
1
2
𝑃(𝑌1 = 𝑌2) (Kruskal, 1957). 
Vargha and Dalancy (1998) called this the measure of stochastic superiority of variable 
𝑌1 over variable 𝑌2. If  𝑇(𝑌1, 𝑌2) = 0.5 then we can say that 𝑌1 and 𝑌2 are stochastically equal or 
identically distributed. Further we can note from Vargha et al. (1998) that when 𝑇(𝑌1, 𝑌2) >
0.5 (or < 0.05), outcomes of 𝑌1 tend to be larger (or smaller) than outcomes of 𝑌2. For 
simplicity, from now we will drop (𝑌1, 𝑌2) from 𝑇(𝑌1, 𝑌2) and let 𝑇 = 𝑃(𝑌1 > 𝑌2) +
1
2
𝑃(𝑌1 = 𝑌2) 
as the measure of relative effect size. 
In terms of 𝑇, MF can be expressed as, 
𝑀𝐹 = 2𝑇 − 1.                         
The measure 𝑇 could be estimated in terms of Wilcoxon rank sum statistics as discussed in Siev 
(2005).  
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1.6 Wilcoxon rank sum statistics and the mitigated fraction 
Wolf and Hogg (1971) showed that 𝑃(𝑌2 < 𝑌1) can be estimated using Wilcoxon rank 
sum statistics as shown below. 
𝑃(𝑌2 < 𝑌1) = ∫𝐹(𝑧)𝑑𝐺(𝑧), where  𝐹 and 𝐺 are the distribution function of 𝑌2 and 𝑌1 
respectively. Since 𝐹 and 𝐺 are unknown, Wolf et al. (1971) showed that the value of 𝑃(𝑌2 < 𝑌1) 
can approximated estimated by using empirical distribution functions as estimates for 𝐹 and 𝐺. 
 𝑃(𝑌2 < 𝑌1) ≈ ∫𝐹𝑌2(𝑧)𝑑𝐺𝑌1(𝑧) =
𝑊1−𝑁1(𝑁1+1)/2
𝑁2𝑁1
 , where 𝐹𝑌2 and 𝐺𝑌1 are empirical distribution 
functions as estimates for 𝐹 and 𝐺 respectively, 𝑊1 is sum of the ranks in control group 
(Wilcoxon rank sum statistics), 𝑁1and 𝑁2 are the number of observations from the control and 
vaccine groups respectively.  
Because 𝑌1 and 𝑌2 are continuous random variables, 𝑃(𝑌1 = 𝑌2) = 0 and  𝑇 = 𝑃(𝑌1 > 𝑌2) and 
𝑀𝐹 = 2𝑇 − 1. 
Now, estimated 𝑀𝐹 will be equal to {
2𝑊1−𝑁1(1+𝑁2+𝑁1)
𝑁2𝑁1
}. This provides a fully non-parametric 
approach for 𝑀𝐹.  
 
1.7 Ridit analysis and 𝑴𝑭 
Ridit was introduced by Bross (1958) and the term ridit is derived from the initials of 
“Relative to an Identified Distribution” and it is analogous to the probit and logit models. Ridit 
assumes an underlying empirical continuous distribution whereas the probit and logit assume 
underlying standard normal and logistic distributions, respectively. Ridit is a non-parametric 
approach for ordinal data whereas the probit and logit are parametric approaches. Ridit analysis 
plays a main role in the estimation of mitigated fraction for an ordinal response. In fact, the mean 
ridit determines the estimated value for the mitigated fraction from an ordinal response. For the 
8 
analysis of ridit, it is important to have a population group to treat as a reference group. Bross 
(1958) mentioned this population group as the ‘identified distribution’. This can be thought as a 
control ( or placebo) group in the usual analysis of treatment versus control. A ridit score is defined 
as the proportion of all individuals from the reference group falling in the lower ranking categories 
plus half the proportion falling in the given category (Fleiss, 2003).  Fleiss (2003) states that the 
ridit analysis assumes there are discrete categories representing intervals of an underlying but 
unobservable continuous distribution. The operations can be viewed as a method of assigning a 
score (or weight) to the graded categories.  
The mean ridit for a given group with same categories of the reference group can be 
calculated and viewed as a probability. Fleiss (2003) states, “The mean ridit for a group is the 
probability that a randomly selected individual from it has a value indicating greater severity or 
seriousness than a randomly selected individual from the standard group.” Similarly, Bross (1958) 
says the mean ridit is an estimate of the chance that an individual in a given class is “worse off” 
than an individual in the reference class. 
 
Mathematical form of ridit analysis 
An alternative approach to selecting scores for ordinal categories used in a ridit analysis is 
to use the data themselves to determine the scores. One such scoring method uses the average 
cumulative proportions for the ordinal response variable (Agresti, 2010).  
For illustration purposes, let 𝑌1 be the observed value of this variable for an individual randomly 
selected from the control (Placebo) group and let 𝑌2 be the response for a randomly selected 
individual from the treatment (Vaccine) group. Let 𝐽 be the number of ordinal categories in both 
vaccine and control groups. 
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Let 𝑝1, 𝑝2, … , 𝑝𝐽 be the proportions for the control group categories and let 𝑞1, 𝑞2, … , 𝑞𝐽 be the 
proportions for vaccine group categories.  For the reference group, the ridit scores for category 𝑗 
is given by 





𝑘=1    𝑓𝑜𝑟 𝑗 = 1,2, … , 𝐽.                           






Following Agresti (2010), it can be shown that 
𝑇(𝑌2, 𝑌1) = 𝑃(𝑌2 > 𝑌1) +
1
2
𝑃(𝑌1 = 𝑌2).  
Using the above results, MF can be expressed in terms of 𝑇(𝑌2, 𝑌1) as, 
𝑀𝐹 = 1 − 2 ∗ 𝑇(𝑌2, 𝑌1). 
Following Agresti (2010), the mean ridit of the control group with respect itself, i.e. 𝑇(𝑌1, 𝑌1), is 
given by 
























The above result clearly shows the reference group compared to itself has the mean ridit of 0.50 
which is intuitively what it should be. If the mean ridit of the treatment group with respect to the 
control group is 0.5, then we can say both groups are similar in terms of the severity.  
1.8 Mitigated fraction from an ordinal response 
Now let us assume there is an interest in a measure of disease severity where the outcome 
variable is ordinal, possibly when observations are clustered or measured longitudinally. Ordinal 
outcomes in terms of measuring disease severity are widely popular in the areas of veterinary 
medicines and epidemiological fields. For example, disease severity might be measured as 
‘none’, ‘light’, ‘mild’, ‘moderate’, or ‘severe’.  Also, it is common in many clinical trials having 
outcomes which are measured on an ordered categorical scale. 
Currently, the 𝑀𝐹 is estimated for continuous responses. Siev (2005) implied that 𝑀𝐹 
can be calculated when the disease severity is graded by some continuous measure or by some 
discrete assessment resulting in unambiguous ranks. Further, the 𝑀𝐹 R-package (Siev, 2012) 
supports only the continuous response variable to calculate 𝑀𝐹. Siev (2005) briefly introduced 
the interest in estimating 𝑀𝐹 for mitigated fraction for ordinal data and he referred the idea of 
using normal latent continuous random variable discussed in Poon (2004) and mean ridit (Bross, 
1958) to estimate 𝑀𝐹 for ordinal data. Latent variable approaches will be discussed in the 
subsequent chapters to estimate 𝑀𝐹 for ordinal data. Even though Siev (2005) very briefly 
introduced the interest in estimating 𝑀𝐹 for mitigated fraction for ordinal data, he never 
discussed any methods explicitly to estimate 𝑀𝐹 for ordinal data. In this work, several methods 
are discussed to estimate 𝑀𝐹 for an ordinal response. A parametric approach assuming a 
generalized linear mixed model (GLMM) with latent variable is developed for estimating 𝑀𝐹 for 
ordinal response. To accomplish this, the following sections are outlined as follows: Chapter 2 
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discusses the theatrical framework, Chapter 3 discusses estimating 𝑀𝐹 when the vaccine and 
placebo groups are in a completely randomized design, Chapter 4 discusses estimating 𝑀𝐹 for 
ordinal clustered data, Chapter 5 briefly discusses estimating 𝑀𝐹 for ordinal data from a 





















Chapter 2 - Theoretical framework 
Multinomial distribution analysis with ordinal data for mitigated fraction is preferable for 
the response variables such as disease severity rating (with possible outcomes none, light, mild, 
moderate, or severe) or approval rating (with possible outcomes strongly disagree, disagree, 
neutral, agree, or strongly agree). 
A multinomial response 𝑌 can be considered for ordered categorical outcomes, which 
could possibly be denoted by 1, 2, 3, … , 𝐽 with probabilities ?̃?𝑗 = 𝑃(𝑌 = 𝑗) for 𝑗 = 1,… , 𝐽. Each 
observation of 𝑌 belongs to exactly one category, i.e. 𝑌 takes a value 𝑗 if a particular ordinal 
observation falls in the 𝑗’th category and the probabilities sum to one, i.e. ∑ ?̃?𝑗 = 1
𝐽
𝑗=1 . 
When 𝑛𝑗  is the number of observations from a given sample belonging to category 𝑗 with  
∑ 𝑛𝑗 = 𝑛
𝐽
𝑗=1 , the probability mass function for the multinomial distribution is  
𝑓(𝑛1, 𝑛2, … , 𝑛𝐽) =
𝑛!







Cumulative link models 
Let 𝑌 denote the response variable for an ordinal observation, and let 𝑿 = (𝑥1, 𝑥2, … , 𝑥𝑝)
′
 
denote a 𝑝-dimensional vector of explanatory variables. 
One can model the relationship between the ordinal random variable 𝑌 and its corresponding 
vector of explanatory variables using the cumulative probability model. 
A basic cumulative link model is 
𝜋𝑗 = 𝐺(𝜂𝑗), 𝜂𝑗 = 𝛾𝑗 − 𝑿
′𝜷 for  𝑗 = 1,… , 𝐽 − 1, 
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where 𝜋𝑗 = 𝑃(𝑌 ≤ 𝑗|𝑿) = ?̃?1 +⋯+ ?̃?𝑗 with ∑ ?̃?𝑗 = 1
𝐽
𝑗=1  are cumulative probabilities; 𝜂𝑗 is the 
linear predictor; 𝜷 = (𝛽1, 𝛽2, … , 𝛽𝑝)
′
 is a 𝑝-dimensional vector of parameters that describe the 
effects of the explanatory variables; and 𝛾𝑗′𝑠, 𝑗 = 1,2, … , 𝐽 are thresholds (also known as cut-points 
or intercepts) and they are representing the baseline value of the transformed cumulative 
probability for category 𝑗.  
The above cumulative link model written as 
𝐺−1[𝑃(𝑌 ≤ 𝑗|𝑿)] = 𝛾𝑗 − 𝑿
′𝜷 = 𝛾𝑗 − 𝛽1𝑥1 −⋯− 𝛽𝑝𝑥𝑝                                                   (1.1) 
for 𝑗 = 1,… , 𝐽 − 1. Here, 𝐺−1(∙) is an arbitrary link function which links the cumulative 
probabilities to the linear predictor. The 𝐺−1(∙) is a (known) monotone-increasing function 
mapping the interval (0, 1) onto the real line (−∞,∞). Here, model (1.1) assumes an identical 
effect 𝜷 of the predictors for each cumulative probability. 
If 𝐺−1 is the inverse of the standard logistic cumulative density function (cdf), then model (1.1) 
is a cumulative logit model, while if 𝐺−1 is the inverse of the standard extreme value (minimum) 
cdf, then model (1.1) is called the cumulative complementary log-log (clog-log) or proportional 
hazards model. Different types of cumulative probability models for ordinal data will briefly be 
discussed in the subsequent sections.  
The cell probabilities, ?̃?1, … , ?̃?𝑗, for the cumulative link modes can be driven as follows 
𝑃(𝑌 = 𝑗|𝑿) = ?̃?𝑗 = 𝐺 (𝛾𝑗 − 𝑿
′𝜷) − 𝐺 (𝛾𝑗−1 − 𝑿
′𝜷) for 𝑗 = 1,… , 𝐽 
with 𝛾0 = −∞ and  𝛾𝐽 = ∞.  
 
2.1 The cumulative logit model 
When the 𝐺−1 in model (1.1) is the inverse of the standard logistic cdf, then the model 
(1.1) is a cumulative logit or proportional odds model given as 
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𝑙𝑜𝑔𝑖𝑡[𝑃(𝑌 ≤ 𝑗|𝑿)] = 𝑙𝑜𝑔
𝑃(𝑌 ≤ 𝑗|𝑿)
1 − 𝑃(𝑌 ≤ 𝑗|𝑿)
= 𝛾𝑗 − 𝑿
′𝜷, 𝑓𝑜𝑟  𝑗 = 1,… , 𝐽 − 1 
and 𝑃(𝑌 ≤ 𝑗|𝑿) can be obtained as, 





 𝑓𝑜𝑟  𝑗 = 1,… , 𝐽 − 1. 
and the cell probabilities under logit model are 










 for 𝑗 = 1, … , 𝐽 
with 𝛾0 = −∞ and  𝛾𝐽 = ∞.  
 
2.1.1 The proportional odds property 
The odds ratio (𝑂𝑅) of observing event 𝑌 ≤ 𝑗 at 𝑿 = 𝑿𝟏 relative to the same event at 
𝑿 = 𝑿𝟐 is 
𝑂𝑅 =
𝑃(𝑌 ≤ 𝑗|𝑿𝟏)/𝑃(𝑌 > 𝑗|𝑿𝟏)
𝑃(𝑌 ≤ 𝑗|𝑿𝟐)/𝑃(𝑌 > 𝑗|𝑿𝟐)
= 𝑒𝑥𝑝((𝑿𝟐 −𝑿𝟏)
′𝜷) 
The cumulative odds ratio is proportional to the difference between 𝑿𝟏 and 𝑿𝟐. The same 
proportionality constant applies to all 𝐽 − 1 logits. Because of this property, following 
McCullagh (1980), the cumulative logit model is often referred to as a proportional odds model. 
 
2.2 The cumulative probit model 
When the 𝐺−1 in model (1.1) is the inverse of the standard normal cdf, then the model 
(1.1) is a cumulative probit model given as 
𝛷−1[𝑃(𝑌 ≤ 𝑗|𝑿)] = 𝛾𝑗 − 𝑿
′𝜷 = 𝛾𝑗 − 𝛽1𝑥1 −⋯− 𝛽𝑝𝑥𝑝 for 𝑗 = 1,… , 𝐽 − 1 
and hence 
[𝑃(𝑌 ≤ 𝑗|𝑿)] = 𝛷(𝛾𝑗 − 𝑿
′𝜷) for 𝑗 = 1,… , 𝐽 − 1, 
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where 𝛷 denotes the cumulative density function of the standard normal distribution. The above 
cumulative probit model links the cumulative probabilities to a linear predictor.  
 
2.3 The cumulative complementary log-log model and cumulative log-log 
The Gumbel distribution is sometimes called the type 1 extreme value distribution and 
has two forms. One is used to model the smallest extreme (minimum) values of various 
distributed outcomes and the other is used to model the largest extreme (maximum) values of 
various distributed outcomes. They are called Gumbel distribution (minimum) and Gumbel 
distribution (maximum) respectively (Wikipedia, 2021 and Agresti, 2010).  
This project report uses the term Gumbel distribution (maximum) for Gumbel distribution 
to model the distribution of the maximum values, and the name Gumbel distribution (minimum) 
for Gumbel distribution to model the distribution of the minimum value. 
 
2.3.1 The Cumulative complementary log-log models (clog-log) 
The Gumbel distribution (minimum) has the cumulative distribution function, 
𝐹(𝑥; 𝜇, 𝜎) = 1 − 𝑒𝑥𝑝 (−𝑒𝑥𝑝 ((𝑥 − 𝜇)/𝜎)) with location parameter μ and scale parameter σ.  
The standard Gumbel distribution (minimum) with location parameter 𝜇 = 0  and scale 
parameter 𝜎 = 1 is given as 𝐹(𝑥) = 1 − 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (𝑥)). 
When the 𝐺−1 in model (1) is the inverse of the standard Gumbel (minimum) cdf then the 
model (1) is a cumulative complimentary log-log (clog-log) model given as 
𝑙𝑜𝑔 (−𝑙𝑜𝑔 (1 − 𝑃(𝑌 ≤ |𝑿)) = 𝛾𝑗 − 𝑿
′𝜷 = 𝛾𝑗 − 𝛽1𝑥1 −⋯− 𝛽𝑝𝑥𝑝 for 𝑗 = 1,… , 𝐽 − 1 
and hence 
𝑃(𝑌 ≤ 𝑗|𝑿) = 1 − 𝑒𝑥𝑝(−𝑒𝑥𝑝((𝛾𝑗 − 𝑿
′𝜷)))  or 𝑗 = 1, … , 𝐽 − 1. 
16 
Here it is to be noted that the above model applies the 𝑙𝑜𝑔 (−𝑙𝑜𝑔) as the link function for 
the complementary of cumulative probabilities and thus the link function is called the 
complimentary log-log (clog-log) link function (Agresti, 2010). 
2.3.2 Cumulative log-log models 
The Gumbel distribution (maximum) has the cumulative distribution function,  
𝐹(𝑥; 𝜇, 𝜎) = 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (−(𝑥 − 𝜇)/𝜎)) with location parameter μ and scale parameter σ.  
The standard Gumbel distribution (maximum) with location parameter 𝜇 = 0  and scale 
parameter 𝜎 = 1 is given as 𝐹(𝑥) = 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (−𝑥)). 
When the 𝐺−1 in model (1) is the inverse of the standard Gumbel (maximum) cdf, then the 
model (1) is a cumulative log-log model given as 
−𝑙𝑜𝑔 (−𝑙𝑜𝑔 (𝑃(𝑌 ≤ 𝑗|𝑿)) = 𝛾𝑗 −𝑿
′𝜷 = 𝛾𝑗 − 𝛽1𝑥1 −⋯− 𝛽𝑝𝑥𝑝 for 𝑗 = 1, … , 𝐽 − 1 
and hence 
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑒𝑥𝑝(− 𝑒𝑥𝑝(−(𝛾𝑗 − 𝑿
′𝜷))) for 𝑗 = 1,… , 𝐽 − 1. 
Here it is to be noted that the above model applies the −𝑙𝑜𝑔 (−𝑙𝑜𝑔) as the link function for the 
cumulative probabilities and thus the link function for the cumulative probabilities is called the 
log-log link function. 
 
2.4 Latent variable motivation 
Following McKelvey and Zavoina (1975), McCullagh (1980), Anderson and Philips 
(1981), Cox (1995), Johnson and Albert (1999), Agresti (2010), and many other authors, one can 
view an ordinal response variable 𝑌 is that it is generated by an unobserved continuous latent 
variable 𝑌∗ with 𝐽 − 1 cut points 𝛾1 < 𝛾2 < ⋯ < 𝛾𝐽−2 < 𝛾𝐽−1, on the continuous latent scale 
such that 𝑌 = 𝑗 if 𝛾𝑗−1 < 𝑌
∗ ≤ 𝛾𝑗. Agresti (2010) notes that it may be sensible to consider an 
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ordinal variable as a necessarily crude measurement of the continuous latent variable 𝑌∗, which 
would be the response variable in an ordinary linear model. The cumulative probability model 
(1) can be implied by a model in which the continuous latent variable 𝑌∗ satisfies an ordinary 
regression model 𝑌∗ = 𝑿′𝜷 + 𝜖 in which 𝜖 has a cumulative distribution function (cdf) 𝐺 with 
constant variance (Anderson et al., 1981). 
Thus, the latent variable 𝑌∗ and the observed response variable 𝑌 give the model with the 
probability that the response variable 𝑌 will fall in the 𝑗th category or below, given 𝑿,  
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷) = 𝐺(𝛾𝑗 − 𝑿
′𝜷). 
Thus, the cumulative probability model (1) can be given in terms of latent variable as 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷) = 𝐺(𝛾𝑗 − 𝑿
′𝜷)                   (1.2). 
Note that in both models (1) and (2), we assume that the predictors 𝑿 do not include a 
column of ones because the constant is absorbed into the cut points. But in some situations, like 
in the Bayesian approach in Chapter 5, we assume that the predictors 𝑿 include a column of ones 
by imposing appropriate constraints on the cut points. Detailed identification constraints will be 
discussed in the next section. 
As mentioned above, the link function to apply for 𝑃(𝑌 ≤ 𝑗|𝑿) to obtain a linear 
predictor is 𝐺−1, the inverse of the cumulative distribution function for the latent variable 𝑌∗. 
That is, 
𝐺−1(𝑃(𝑌 ≤ 𝑗|𝑿)) = 𝛾𝑗 − 𝑿
′𝜷 (Agresti, 2010). 
When ϵ follows an independent normal distribution with mean 0 and constant variance 𝜎2,  
𝑁(0, 𝜎2) then, 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) 
                           = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷) 
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                           = 𝑃(𝑍 ≤ (𝛾𝑗 − 𝑿
′𝜷)/𝝈), hence 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) =  𝛷((𝛾𝑗 − 𝑿
′𝜷)/𝜎)                                                                                                 (1.3) 
where 𝑍 follows a standard normal distribution and 𝛷 denotes the standard normal cumulative 
distribution function. The 𝛾𝑗
′s, 𝜷 and σ can be identifiable if 𝑌∗ is directly observed but since 𝑌∗ is 
unobservable, not all parameters are identifiable. For identifiable easiness, without loss of 
generality, 𝜎 can be set to 1. Jackman (2000) discussed possible identification constraints which 
are displayed in Table 2.1. 
With 𝜎 = 1 for the expression in the equation (1.3), 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) =  𝛷((𝛾𝑗 − 𝑿
′𝜷). 
Now it is straight forward that 𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) =  𝛷((𝛾𝑗 −𝑿
′𝜷) and this shows a 
cumulative probit model arise when 𝜖 follows a standard normal distribution. We will discuss 




Table 2.1. Identification Constraints 
Constrains options 𝛽 𝜎 𝛼 
1 unconstrained 
fixed 
e.g., 𝜎 = 1 
one γj fixed 
e.g., γ1 = 0 
2 
drop intercept, 
𝛽0 = 0 
fixed 
e.g., 𝜎 = 1 
unconstrained 
3 unconstrained unconstrained 
two γj′s fixed 
e.g., 𝛾1, 𝛾2 = 0 




2.4.1 Probit link model motivation 
When 𝜖 follows a standard normal distribution, 𝜖~𝑁(0,1), a normal continuous latent 
variable is given as 𝑌∗~𝑁(𝑿′𝜷, 1), and under this normal latent variable: 
 𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) 
                                                        = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷) 
                                                       = 𝑃(𝑍 ≤ (𝛾𝑗 − 𝑿
′𝜷) ) 
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) =  𝛷((𝛾𝑗 − 𝑿
′𝜷)). 
where 𝑍 follows a standard normal distribution and 𝛷 denotes the standard normal cdf. Thus, a 
probit model arises under the normal latent variable.  
 
2.4.2 Logit link model motivation 
When 𝜖 follows independent standard logistic distribution, 𝑙𝑜𝑔𝑖𝑠𝑡𝑖𝑐(0, 1) with location 
parameter 𝜇 = 0  and scale parameter 𝜎 = 1, 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) 
                            = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷 ) 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝐺(𝛾𝑗 − 𝑿
′𝜷 )        
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) =
𝑒𝑥𝑝 ((𝛾𝑗 − 𝑿
′𝜷 )
1 + 𝑒𝑥𝑝 ((𝛾𝑗 − 𝑿′𝜷 )
                    






2.4.3 Complimentary log-log model link model motivation 
When ϵ follows independent standard Gumbel (minimum) distribution, 𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛(0, 1) 
with location parameter 𝜇 = 0  and scale parameter 𝜎 = 1, 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) 
                                = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷 ) 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝐺(𝛾𝑗 − 𝑿
′𝜷 )   
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 1 − 𝑒𝑥𝑝(− 𝑒𝑥𝑝((𝛾𝑗 − 𝑿
′𝜷))) 
where 𝐺 denotes the standard Gumbel (minimum) cdf. Thus, a complimentary log-log model 
arises under the Gumbel (minimum) latent variable.  
 
2.4.4 log-log model link model motivation 
When ϵ follows independent standard Gumbel (maximum) distribution, 
𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥(0, 1) with location parameter 𝜇 = 0  and scale parameter 𝜎 = 1, 
     𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑃(𝑿
′𝜷 + 𝜖 ≤ 𝛾𝑗) 
                                = 𝑃(𝜖 ≤ 𝛾𝑗 − 𝑿
′𝜷 ) 
𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝐺(𝛾𝑗 − 𝑿
′𝜷 )   
𝑃(𝑌 ≤ 𝑗|𝑿) = 𝑃(𝑌∗ ≤ 𝛾𝑗|𝑿) = 𝑒𝑥𝑝(−𝑒𝑥𝑝(−(𝛾𝑗 − 𝑿
′𝜷)))      
where 𝐺 denotes the standard Gumbel (maximum) cdf. Thus, a log-log model arises under the 
Gumbel (maximum) latent variable.  
In summary, the latent variable structure gives rise to probit, logit, log-log, and clog-log 
models when 𝜖 respectively follows distributions of a standard normal, standard logistic, standard 
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Gumbel (maximum), and standard Gumbel (minimum) cdf’s. Table 2.2 shows the distributions of 
𝜖 and the form of link functions 𝐺−1(∙). 
 
Table 2.2. Distributions of 𝝐 and form of 𝑮−𝟏(∙) 
Name/Model Distribution of 𝜖 Link function (𝐺−1) Inverse link (𝐺) 
probit 𝑁(0,  1) 𝛷−1(𝛾) 𝛷(𝜂) 
logit 𝑙𝑜𝑔𝑖𝑠𝑡𝑐(0,  1) 𝑙𝑜𝑔𝑖𝑡(𝛾) = 𝑙𝑜𝑔 [𝛾/(1 − 𝛾)] 𝑒𝑥𝑝(𝜂) /(1 + 𝑒𝑥𝑝(𝜂)) 
clog-log 𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛(0,1) 𝑙𝑜𝑔[−𝑙𝑜𝑔 (1 − 𝛾)] 1 − 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (𝜂)) 
log-log 𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥(0,1) −𝑙𝑜𝑔[−𝑙𝑜𝑔 (𝛾)] 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (−𝜂)) 
 
In this table, 𝛾 denotes cumulative probabilities and 𝜂 denotes linear predictor. 𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛 and 
𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥 denote, respectively, Gumbel (minimum) distribution and Gumbel (maximum) 
distribution. 
 
2.5 Maximum likelihood (ML) estimation for cumulative link models parameters 
Following Agresti (2010), for subject 𝑖, let 𝑦𝑖𝑗 = 1 if 𝑦𝑖 = 𝑗 and let 𝑦𝑖𝑗 = 0 otherwise, 
𝑖 = 1,2, … , 𝑛. Then 𝐸(𝑌𝑖𝑗) = ?̃?𝑗(𝑿𝑖), the probability that observation 𝑖 with explanatory variable 
values 𝑿𝒊 falls in category 𝑗. With the independent observations, we obtain the likelihood 
function by substituting 𝐺(𝛾𝑗 − 𝑿𝒊


































The log-likelihood function is 
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𝐿(𝜸, 𝜷) =∑∑𝑦𝑖𝑗𝑙𝑜𝑔[𝐺(𝛾𝑗 − 𝑿𝒊







We can see that the log-likelihood function is function of 𝛾𝑗′s and 𝜷 after observing the 
observations 𝑦𝑖𝑗. As discussed in Agresti (2010), each log-likelihood equation can be obtained 
by differentiating 𝐿(𝜸, 𝜷) with respect to a particular parameter and equating the derivative to 
zero. And then iterative methods are used to solve the log-likelihood equations and then obtain 
the ML estimates of the model parameters. Generally, the Newton-Rapson algorithm can be used 
to maximize the log-likelihood function to yield ML estimates. 
 
2.6 Bootstrap methods and bootstrap confidence intervals 
Bootstrap methods can be used to construct confidence intervals. In this section, most of 
terms, and notation follow closely to those found in Efron and Tibshirani (1993). 
Let 𝑿 = (𝑥1, 𝑥2, … , 𝑥𝑛) be a random sample from an unknown probability distribution 𝐹 and we 
wish to estimate a parameter of interest 𝜃 = 𝑡(𝐹) based on 𝑿. Let 𝜃 = 𝑠(𝑿) be a statistic 
calculated from 𝑿 such that 𝜃 estimate the parameter of interest 𝜃. The bootstrap method can be 
used to estimate the standard error of 𝜃. Bootstrap methods depend on the bootstrap sample. Let 
?̂? be the empirical distribution, having probability 1/𝑛 on each of the observed values 𝑥𝑖, 𝑖 =
1,2, … , 𝑛. A bootstrap sample 𝑿∗ can be defined as 𝑿∗ = (𝑥1
∗, 𝑥2
∗, … , 𝑥𝑛
∗) where 𝑿∗ is a random 
sample of size 𝑛 drawn from an empirical distribution ?̂? of the sample 𝑿. Here, the 𝑿∗ will be 
treated as a resampled version of 𝑿. This means that the data points (𝑥1
∗, 𝑥2
∗, … , 𝑥𝑛
∗) are a random 
sample of size 𝑛 drawn with replacement from the population of 𝑛 data points (𝑥1, 𝑥2, … , 𝑥𝑛). 
Corresponding to a bootstrap data set 𝑿∗, 𝜃∗will be a bootstrap replication of 𝜃 such that 
𝜃∗ = 𝑠(𝑿∗). 
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The quantity 𝑠(𝑿∗) can be calculated by applying the same function 𝑠(∙) as was applied to 𝑿. 
In the need of a given statistical properties, such as standard error of the estimate 𝜃, it is 
necessary to have the sampling distribution of 𝜃. 
Let 𝑠𝑒𝐹𝜃 be the bootstrap estimate and it is the standard error of the statistics 𝜃. The 𝑠𝑒𝐹𝜃 is a 
plug-in estimate that uses the empirical distribution ?̂? in place of the unknown distribution 𝐹. 
That is, the bootstrap estimate of 𝑠𝑒𝐹𝜃 can be defined by 𝑠𝑒𝐹𝜃
∗(Efron et al.,1993). 
As Efron et al. (1993) stated, the bootstrap algorithm works by drawing many independent 
bootstrap samples, evaluating the corresponding bootstrap replications, and estimating the 
standard error of 𝜃 by the empirical standard deviation of the replications. The result is called the 
bootstrap estimate of standard error, denoted by 𝑠?̂?𝐵, with 𝐵 is the number of bootstrap samples. 
The following gives the detailed description of the bootstrap procedure for estimating the 
standard error of 𝜃 = 𝑠(𝑿) from the observed data 𝑿. The following algorithm has been directly 
taken from Efron et al. (1993). 
The bootstrap algorithm procedure for estimating the standard errors: 
1. First, select 𝐵 independent number of bootstrap samples 𝑿∗1, 𝑿∗2, 𝑿∗3, …𝑿∗𝐵, each 
consisting of 𝑛 data values drawn with replacement from 𝑿. 
2. Evaluate the bootstrap replication, 𝜃∗, corresponding to each bootstrap sample, 
𝜃∗(𝑏) = 𝑠(𝑿∗𝑏)                𝑏 = 1,2, … , 𝐵.             












where 𝜃∗(∙) = ∑ 𝜃∗(𝑏)/𝐵𝐵𝑏=1 . Using the generated bootstrap replications (𝜃
∗1, … , 𝜃∗
𝐵
), 
confidence intervals for 𝜃 can be constructed. 
Percentile interval using bootstrap samples 
Let 𝜃∗(𝛼) indicate the 100 ∗ 𝛼th percentile of 𝐵 bootstrap replications 
𝜃∗(1), 𝜃∗(2),… , 𝜃∗(𝐵). The percentile interval (𝜃𝑙𝑜 , 𝜃𝑢𝑝) of intended coverage 1 − 2𝛼, can be 
obtained directly from these percentiles, with 𝜃𝑙𝑜 and 𝜃𝑢𝑝 are lower control and upper control 
confidence limits, respectively. 
The percentile interval (𝜃𝑙𝑜 , 𝜃𝑢𝑝) will be equal to (𝜃
∗(𝛼), 𝜃∗(1−𝛼)), i.e. (𝜃𝑙𝑜 , 𝜃𝑢𝑝) =
(𝜃∗(𝛼), 𝜃∗(1−𝛼)). 
An example from Efron et al. (1993), if 𝐵 = 2000 and 𝛼 = .05, then the percentile 
interval (𝜃∗(.05), 𝜃∗(.95)) will be given by the 100th (i.e. 𝜃∗(100))to the 1900th (i.e. 𝜃∗(1900)) 
ordered values of the 2000 numbers 𝜃∗(𝑏), 𝑏 = 𝐼, 2, … ,2000. 
Bias Corrected and Accelerated Confidence Intervals (𝑩𝑪𝒂) 
Following Efron et al. (1993), the 𝐵𝐶𝑎 interval of intended coverage, 1 − 2𝛼, will be given by 
𝐵𝐶𝑎: (𝜃𝑙𝑜 , 𝜃𝑢𝑝) = (𝜃
∗(𝛼1), 𝜃∗(𝛼2)),  
where 









).   
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Chapter 3 - Estimation of mitigated fraction for two groups on an 
ordinal categorical response variable 
In this chapter, several statistical methods will be discussed to estimate the mitigated 
fraction for two independent groups. An experiment involving two treatments such as vaccine 
and placebo will be considered for the initial study. Later, possible methods will be discussed for 
studies where more than two independent groups are compared to estimate the mitigated fraction.  
In an experiment involving two independent groups, experimental units are randomly divided 
into two treatment groups, experimental units in one group are treated with the vaccine, and 
experimental units in the other group are treated with a placebo. The response to treatment for 
each subject in terms of disease severity will be assumed to be an ordinal outcome. 
Here, latent variable techniques and the values of the latent variables will mainly be used 
to estimate the mitigated fraction from ordinal response variables. As discussed in Chapter 2, an 
observed ordinal response is often taken to reflect an unobserved continuous latent variable. 
Cox (1995) worked with location-scale cumulative models for ordinal data to investigate 
several problems on medical diagnosis. Cox (1995) applied disease severity on a latent 
continuous random variable scale to investigate problems, namely, ultrasound ratings as an 
ordinal measure of disease severity of different cancer types; severity of nausea on a 6-point 
scale was measured in groups of patients who received chemotherapy without and with cisplatin; 
and severity of coronary artery disease. Whitehead, Omar, Higgins, Savaluny, Turner and 
Thompson (2001) discussed a latent logistic random variable for analyzing ordinal responses 
with applications on medical diagnosis. Recently, Saho, Ma, Chen, Pan and You (2020) 
discussed a latent continuous random variable scale to investigate injury severity in truck-
involved rear-end collisions from ordinal outcomes. Detailed discussion about latent variable 
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techniques can be found in Agresti (2010). Moreover, the latent variable techniques contribute 
significantly to the ordinal data analysis via the data augmentation technique. Especially, the 
Bayesian methods have become popular because the data augmentation techniques can be used 
effectively using latent variables. Albert and Chib (1993) used data augmentation in their 
implementations of the ordinal probit models on the binary and ordinal response so that the full 
conditional distributions of parameters in the Gibbs sampler would be closed form of densities. 
Notably, in some problems, the values of the latent variables may be of interest. For example, 
Albert (1992) used the values of the latent variable to estimate the polychoric correlation 
coefficient between two ordinal variables. Especially, Poon (2004) discussed a latent normal 
distribution model for analyzing ordinal responses with applications on medical diagnosis. 
Poon’s (2004) method was later referred by Siev (2005) to estimate 𝑀𝐹 for ordinal response. 
 
3.1 Estimation of mitigated fraction for two groups  
Assume that there is a single factor of treatment type with two levels (vaccine and 
control) as an explanatory variable. Let 𝑥1 denote the explanatory variable as a group indicator 
for an observation, where 𝑥1 = 1 for the control group and 𝑥1 = 0 for the vaccine group. Also, 
let 𝑌 denote an independent ordinal random variable with 𝐽 categories. The cumulative 
probability model will be: 
𝜋𝑗 = 𝐺(𝜂𝑗), 𝜂𝑗 = 𝛾𝑗 − 𝛽1𝑥1 for  𝑗 = 1,… , 𝐽 − 1, 
where 𝜂𝑗 is the linear predictor, 𝐺 is inverse of an arbitrary link function, and   
𝜋𝑗 = 𝑃(𝑌 ≤ 𝑗|𝑥1) = ?̃?1 +⋯+ ?̃?𝑗 with ∑ ?̃?𝑗 = 1
𝐽




The components for the model summary for this vaccine study are as follows. 
• Linear predictor∶ 𝛾𝑗 − 𝛽1𝑥1 
• Distribution: 𝑌~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑛, ?̃?1, ?̃?2, … , ?̃?𝐽) 
• Link: 𝐺−1such that 𝐺−1(𝑃(𝑌 ≤ 𝑗|𝑥1)) = 𝜂𝑗 
The underlying latent variable 𝑌∗ for above model will be  
𝑌∗ = 𝛽1𝑥1 + 𝜖                                                                                          (3.1) 
Agresti and Kateri (2017) denoted that it may be sensible to consider an ordinal categorical 
variable as a necessarily crude measurement of the continuous latent variable 𝑌∗, which would 
be the response variable in an ordinary linear model such as a model in the expression (3.1). The 
distribution of 𝑌∗ will be determined by the cdf of the error term 𝜖.  
Following model in the expression (3.1), let 𝑌1
∗ and 𝑌2
∗ denote independent underlying latent 
random variables such that when 𝑥1 = 1 then 𝑌1
∗ for the control group and when 𝑥1 = 0 then 𝑌2
∗ 
for the vaccine group. Siev (2005) and Agresti et al. (2017) argued that the measure 𝑇 (𝑇 =
𝑃(𝑌1 > 𝑌2) +
1
2
𝑃(𝑌1 = 𝑌2)) applies directly to this latent variable model in the expression (3.1). 
In the following sections, different link functions are used to estimate the mitigated fractions; 
these are probit, logit, clog-log and log-log.  
3.2 Estimation of mitigated fraction under probit link 
When the probit link function is used, then the cumulative probit model will be 
[𝑃(𝑌 ≤ 𝑗|𝑥1)] = 𝛷(𝛾𝑗 − 𝛽1𝑥1) for 𝑗 = 1,… , 𝐽 − 1. 
The underlying latent variable, 𝑌∗, will be  𝑌∗ = 𝛽1𝑥1 + 𝜖. 
For this probit model case, as 𝜖 follows the standard normal distribution, a normal latent variable 
𝑌∗ given as 𝑌∗~𝑁(𝛽1𝑥1, 1). Letting 𝑌1
∗ and 𝑌2
∗ denote independent underlying latent variables 
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such that when 𝑥1 = 1 then 𝑌1
∗ for the control group and when 𝑥1 = 0 then 𝑌2
∗ for the vaccine 
group. Thus, 𝑌1
∗~𝑁(𝛽1, 1) and 𝑌2








∗ > 0) 
              𝑃(𝑌1
∗ − 𝑌2









         𝑃(𝑌1
∗ − 𝑌2
∗ > 0) = 𝑃 (𝑍 > −
𝛽1
√2




where 𝑍 follows a standard normal distribution, 𝛷 denotes the standard normal cumulative 







∗) and for the underlying continuous latent 
variable 𝑃(𝑌1
∗ = 𝑌2
∗) = 0 and then 𝑇 = 𝑃(𝑌1
∗ > 𝑌2
∗). 
𝑀𝐹 = 2𝑇 − 1 = 2 ∗ 𝛷 (
𝛽1
√2
) − 1 
3.3 Estimation of mitigated fraction under logit link 
When the logit link function is used, then the cumulative logit model will be 
[𝑃(𝑌 ≤ 𝑗|𝑥1)] =
𝑒𝑥𝑝 (𝛾𝑗−𝛽1𝑥1  )
1+𝑒𝑥𝑝 (𝛾𝑗−𝛽1𝑥1  )
 for 𝑗 = 1,… , 𝐽 − 1. 
The underlying latent variable, 𝑌∗, will be  𝑌∗ = 𝛽1𝑥1 + 𝜖. 
Under the logit model, as 𝜖 follows a standard logistics distribution, a latent variable will be 
given as 𝑌∗~𝑙𝑜𝑔𝑖𝑠𝑡𝑖𝑐(𝛽1𝑥1, 1) and thus 𝑌1
∗ ~𝑙𝑜𝑔𝑖𝑠𝑡𝑖𝑐(𝛽1, 1) and 𝑌2
∗~𝑙𝑜𝑔𝑖𝑠𝑡𝑖𝑐(0,1). Now when 
it comes to the distribution of (𝑌1
∗ − 𝑌2
∗), this one does not follow a logistic distribution or any 
other closed form distribution. A numerical solution can be performed using Monte Carlo 
simulation methods to estimate the value of 𝑃(𝑌1
∗ > 𝑌2
∗). 
Let us briefly discuss Monte Carlo integration methods.  
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3.2.1 Monte Carlo integration 
Monte Carlo methods are numerical techniques which rely on random sampling to 
approximate a result of interest. Monte Carlo integration applies this process to the numerical 
estimation of integrals when an analytical solution to an integration problem is not feasible or 
hard to implement. 
Expected value of a random variable 
Let 𝑋 be a random variable with a probability density function 𝑓(𝑥). Suppose that our 
goal is to find the expected value or expectation of a function of the random variable 𝑋, say 
𝑔(𝑋). The expected value or expectation of 𝑔(𝑥) over a domain µ(𝑥) is defined as 
𝐸[𝑔(𝑋)] = ∫ 𝑔(𝑥)𝑓 (𝑥)𝑑µ(𝑥)
µ(𝑥) 
. 
If 𝑥1, . . . , 𝑥n is a random sample from 𝑓(𝑥), then the strong law of large numbers (SLLN) ensures 







→ 𝐸[𝑔(𝑋)] = ∫ 𝑔(𝑥)𝑓 (𝑥)𝑑µ(𝑥)
µ(𝑥) 
 
as 𝑛 → ∞. 
3.2.2 Expected value of an indicator variable 
Given a probability space (𝛺 , ℱ, 𝑃) with 𝐴 ∈ ℱ, the indicator variable 𝐼𝐴: 𝛺 → ℝ is 
defined by 𝐼𝐴(𝜔) = 1 if 𝜔 ∈ 𝐴, otherwise 𝐼𝐴(𝜔) = 0. Here 𝛺 is the sample space; ℱ is 𝜎-field or 
𝜎-algebra; 𝑃 is probability measure mapping from ℱ to [0,1]; and 𝐴 is a subset of 𝛺 (Rosenthal, 
2006). 
The mean value of 𝐼𝐴(𝜔), that is 𝐸(𝐼𝐴(𝜔)) will be given as 𝐸(𝐼𝐴(𝜔)) = 𝑃(𝐴). 
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Using the above fact, the value of 𝑃((𝑌1
∗ > 𝑌2
∗) will be equal to the expected value of the 
indicator random variable 𝐼(𝑌1∗>𝑌2∗), 
𝑃(𝑌1
∗ > 𝑌2
∗) = 𝐸(𝐼(𝑌1∗>𝑌2∗)) 
where 𝐼(𝑌1∗>𝑌2∗) = 1 if 𝑌1
∗ > 𝑌2








as 𝑛 → ∞ by the SLLN. 
Now the estimation for 𝑃(𝑌1
∗ > 𝑌2





𝑖=1 , and thus the estimated  MF 





𝑖=1 − 1. 
An alternative way to estimate the value of 𝑃(𝑌1
∗ > 𝑌2
∗),  a normal approximate solution 
can be deployed for the logistic distribution. The logistic distribution is a location-scale family, 
and it is very similar to the normal distribution. Both distributions are symmetric and bell-
shaped, though the logistic distribution has heavier tails than normal distribution. Due to these 
similarities, it is appropriate to approximate the logistic distribution using a normal distribution. 
Let 𝐹(𝑥) = (1 + 𝑒−𝑥)−1 be the logistic cumulative density function and 𝐺(𝑥) be the normal 
cumulative distribution function with mean 0 and standard deviation δ and thus logit(x) ≈
𝛿 ∗ 𝛷−1(𝑥). Haley (1952) outlined a theoretical derivation of 𝛿 = 1.702 which was based on 




∥ 𝐹(𝑥) − 𝐺(𝑥) ∥2. Johnson and Kotz (1970) showed graphically 
that a factor 𝛿 =
𝜋
√3
(15/16) = 1.70044 would approximate the logistic distribution. Further, 
Gregory Camilli (1994) reframed Haley’s (1952) work, discussed the minimax criteria in detail, 
and showed the same normal approximation to the logistics distribution with 𝛿 = 1.70174. 
Savalei (2006) proposed a value for 𝛿 = 1.749 based on minimizing Kullback-Leibler (KL) 
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information. Therefore, the standard logistic distribution will be approximated by a normal 




∗~𝑁(0, 𝛿2), where δ is the scale parameter and now 
𝑃(𝑌1
∗ − 𝑌2
∗ > 0) ≈ 𝛷 (
𝛽1
√2𝛿
) and it follows immediately that estimated 𝑀𝐹 = 2 ∗ 𝛷 (
𝛽1
√2𝛿
) − 1. 
 
3.3 Estimation of mitigated fraction under log-log link 
When the log-log link function is used, then  
[𝑃(𝑌 ≤ 𝑗|𝑥1)] = 𝑒𝑥𝑝(−𝑒𝑥𝑝(−𝛾𝑗 + 𝛽1𝑥1  )) for 𝑗 = 1,… , 𝐽 − 1. 
The underlying latent variable, 𝑌∗, will be  𝑌∗ = 𝛽1𝑥1 + 𝜖. 
Under the log-log model, as 𝜖 follows a standard Gumbel distribution (maximum), a 
latent variable will be given as 𝑌∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥 (𝛽1𝑥1, 1) and thus 𝑌1
∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥(𝛽1, 1) and 
𝑌2
∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑎𝑥(0,1). The standard Gumbel maximum distribution with location parameter 
equals to 0  and scale parameter equals to 1 is given as 𝐹(𝑥) = 𝑒𝑥𝑝 (−𝑒𝑥𝑝 (−𝑥)). Following 
Agresti et al. (2017) and McFadden(1974), the distribution of (𝑌1
∗ − 𝑌2
∗) follows a logistic 
distribution, (𝑌1
∗ − 𝑌2










3.4 Estimation of mitigated fraction under clog-log link 
When the clog-log link function is used, then the cumulative logit model will be 
[𝑃(𝑌 ≤ 𝑗|𝑥1)] = 1 − 𝑒𝑥𝑝(−𝑒𝑥𝑝((𝛾𝑗 − 𝛽1𝑥1))) for 𝑗 = 1,… , 𝐽 − 1. 
The underlying latent variable, 𝑌∗, will be  𝑌∗ = 𝛽1𝑥1 + 𝜖. 
Under the logit model, as 𝜖 follows a standard Gumbel distribution (minimum), an underlying 
latent variable will be given as 𝑌∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛 (𝛽1𝑥1, 1) and thus 𝑌1
∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛(𝛽1, 1) and 
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𝑌2
∗~𝐺𝑢𝑚𝑏𝑒𝑙𝑚𝑖𝑛(0,1). Now when it comes to the distribution of (𝑌1
∗ − 𝑌2
∗), this one does not 
follow a Gumbel distribution (minimum) or any other closed form distribution. The Monte Caro 
simulation methods was used to estimate 𝑝(𝑌1
∗ − 𝑌2
∗). Thus, it immediately follows the 
estimation for 𝑃(𝑌1
∗ > 𝑌2





𝑖=1 , and thus the estimated  𝑀𝐹 will be 





𝑖=1 − 1. 
3.5 True value for mitigated fraction 
Let 𝜋𝑖𝑗 be the probability for the j
th category for ith group (either placebo or vaccine) with 𝑗 =
1,2, … , 𝐽 and 𝑖 = 1,2, then the 𝑇 = 𝑃(𝑌1 > 𝑌2) +
1
2
𝑃(𝑌1 = 𝑌2) can be calculated by 







for 𝑗, 𝑘 = 1,2, … , 𝐽 (Agresti et al., 2017).  
If the true values for 𝜋𝑖𝑗′s are known, then 𝑀𝐹 = 2𝑇 − 1. 
If the true values for 𝜋𝑖𝑗′s  are not known, then the estimated mitigated fraction equals 2?̂? − 1 
with 







where ?̂?1𝑗 and ?̂?2𝑘 are fitted values from the corresponding link function of cumulative 
probability model. It is to be noted that the mitigated fraction can be estimated without latent 
variable assumption using the above measure and estimated 𝑀𝐹 equal to 2?̂? − 1. 
3.6 Simulation study 
A simulation study was conducted to assess the performance of the proposed method to calculate 
the mitigated fraction. The performance is evaluated by computing the confidence interval for 
𝑀𝐹 using the criteria of coverage probability. That is the proportion of time the true parameter 
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value of the mitigated fraction contained within the confidence interval. All confidence intervals 
were calculated using bootstrap method described in Section 2.6.  Details of this simulation study 
are given below. 
First define a response variable that comes from a multinomial distribution, i.e. 
𝑛1, 𝑛2, … , 𝑛𝐽~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁, ?̃?1, ?̃?2, … , ?̃?𝐽). 
• 𝑛𝑗  denotes the number of observations in category 𝑗 (𝑗 = 1,… , 𝐽) with ∑ 𝑛𝑗 = 𝑁
𝐽
𝑗=1 , where 
𝑁 is the total number of observations for each treatment. 
• ?̃?𝑗 is the probability a subject falls into the 𝑗
th category with ∑ ?̃?𝑗 = 1
𝐽
𝑖=1 . 
• For this simulations study, five ordinal categories (𝑐0, 𝑐1, 𝑐2, 𝑐3 and 𝑐4) were considered in 
the order of increasing severity, i.e. 𝑐0 is the lowest level of the categories and 𝑐4 is the 
highest level of the categories. 
• A single explanatory variable, 𝑥1, was used as a group indicator with 𝑥1 = 1 for the control 
group and 𝑥1 = 0 for the vaccine group. 
The simulation study was conducted using the following model. Let 𝜋𝑗 be the cumulative 
probabilities such that 𝜋𝑗 = 𝑃(𝑌 ≤ 𝑗|𝑥1) = ?̃?1 +⋯+ ?̃?𝑗 with ∑ ?̃?𝑗 = 1
𝐽
𝑗=1 .  
The cumulative probability model will be: 
𝜋𝑗 = 𝐺(𝜂𝑗), 𝜂𝑗 = 𝛾𝑗 − 𝛽1𝑥1 for  𝑗 = 1,… , 𝐽 − 1, 
where 𝜂𝑗 is the linear predictor, 𝐺 is inverse of an arbitrary link function.  
The simulation consists of the following steps: 
1. For given values of 𝛾1, 𝛾2, 𝛾3, 𝛾4, and 𝛽1, the linear predictor, 𝜂𝑗 was calculated. The 
values for 𝛾1, 𝛾2, 𝛾3, 𝛾4, and 𝛽1 used in the simulation study are given in the description of 
the Table 3.1. 
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2. Probabilities (?̃?1, ?̃?2, ?̃?3, ?̃?4, ?̃?5) for vaccine and control groups were found based on the 
following model with given a link function. 
𝑃(𝑌 ≤ 𝑗|𝑥1) = 𝐺(𝜂𝑗)  for 𝑗 = 1,2,3,4. 
Note: The cell probabilities (?̃?1, ?̃?2, … , ?̃?𝐽) can be found in such a way that ?̃?𝑗 = 𝜋𝑗 −
𝜋𝑗−1 for 𝑗 = 2, . . , 𝐽 with ?̃?1 = 𝜋1 and 𝜋𝐽 = 1. 
3. Using the probabilities, i.e. ?̃?1, ?̃?2, ?̃?3, ?̃?4, ?̃?5, for vaccine and control, independent 
samples containing 100 observations each were generated for the two treatment groups 
respectively (i.e.100 observations for control group and 100 observations for vaccine 
group. 
A total of 10,000 simulated data sets were generated for each parameter setting for a given link 
function. For each data set, a 95% confidence interval for the mitigated fraction was found using 
the bootstrap technique discussed in Section 2.6. The simulation results for all link functions are 
presented in Table 3 where the true value of 𝑀𝐹 has been calculated using the method discussed 
















95% CI for the true 
coverage rate 
log-log 0.9524 (0.94813, 0.95667) 
probit 0.9521 (0.94783, 0.95637) 
clog-log (Monte Carlo simulation) 0.9511 (0.94683, 0.95537) 











) 0.9533 (0.94903, 0.95757) 
𝛿 = 1.749  0.9546 (0.95033, 0.95887) 
𝛿 = 1.702 0.9526 (0.94833, 0.95687) 
Agresti (2017) 0.952 (0.94773, 0.95627) 
The values for  𝛾1 = −1.5, 𝛾2 = −0.3, 𝛾3 = 1, 𝛾4 = 2, and 𝛽1 = 0.3 are used for this simulation 
study. 
 
From Table 3.1, it is evident that the latent variable approach to calculate 𝑀𝐹 yields promising 
results. All, but one, of the 95% CI for the true coverage rate contains the true coverage rate 
(0.95) based on the 10,000 simulations.  
3.7 Model comparison and model selection 
Different link functions such as probit, logit, loglog and cloglog can be used to estimate the 
mitigated fraction. Based on the simulation study, all link functions give promising results to 
estimate the mitigated fraction. In the light of selecting the best link function to estimate the 
mitigated fraction, a simulation study was conducted. The best link function will be selected 
based on the percentage of bias-to-true value of mitigated fraction.  
The simulation consists of the following steps: 
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1. Using the probabilities, i.e. ?̃?1, ?̃?2, ?̃?3, ?̃?4, ?̃?5, as described in Section 3.6, for vaccine and 
control, independent samples containing 100 observations each were generated for the 
two treatment groups respectively (i.e.100 observations for control group and 100 
observations for vaccine group. 
2. Step 1 was repeated and a total of 10,000 simulated data sets were randomly generated 
for each parameter setting for a given link function. For each data set, the mitigated 
fraction was found using the latent variable approach, that is 10,000 estimated mitigated 
fraction values were found using the latent variable approach. 
3. The mean value of the 10,000 estimated mitigated fraction values was found for each link 
function. 
4. The true value of the mitigated fraction was found for each link function using the 
method discussed in Section 3.5. 
5. The bias was found for each link function as follows 
𝐵𝑖𝑎𝑠 =  𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 10,000 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑚𝑖𝑡𝑖𝑔𝑎𝑡𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑣𝑎𝑙𝑢𝑒𝑠
− 𝑡𝑟𝑢𝑒 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑖𝑔𝑡𝑎𝑔𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛. 
The simulation results for all link functions are presented in Table 3.2. 
 




True Value Bias 
Bias-to-true 
value percentage 
Probit 0.09634182 0.08563379 0.01070803 12.50% 
Logit  
(Monte Carlo simulation) 
0.08948851 0.0766 0.01289 16.83% 
loglog 0.08744318 0.07650079 0.01094 14.30% 
cloglog 0.1443742 0.1244831 0.01989 15.98% 
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3.8 Real data analysis 
This data set is from Poon (2004), and the origin of this data set was found in Whitehead 
et al. (2001). This data set was used as a benchmark for this analysis and was collected in a 
vaccine trial on administering the anti-cholinesterase drug tacrine to patients with Alzheimer’s 
disease. Patients receiving tacrine (𝑇) and placebo (P) are, respectively, classified into five 
categories: ‘very much improved’ (𝑐0), ‘minimally improved’ (𝑐1), ‘no change’ (𝑐2), ‘minimally 
worse’ (𝑐3) and ‘very much worse’ (𝑐4). Here ‘𝑐0’ is the clinically best response and ‘𝑐4’ is the 
worst (order of increasing disease severity). Whitehead et al. (2001) and Poon (2004) have 
suggested that there is a tendency for patients receiving the treatment ‘Tacrine’ to have better 
responses than those receiving placebo. The data is given in Table 3.3 and the analysis results are 
presented in the Table 3.4. As discussed in the Section 3.5, the mitigated fraction can be 
estimated without using the latent variable, and the analysis results are presented in the Table 
3.5. 
 
Table 3.3. Patients with Alzheimer’s disease for the tacrine study 
Severity P T 
𝑐0 2 4 
𝑐1 22 23 
𝑐2 54 45 
𝑐3 29 22 
𝑐4 3 2 
Total 110 96 
Data source: Poon, W. (2004). A latent normal distribution model for analyzing ordinal 







Table 3.4. Results of estimated values for the mitigated fraction for the Tacrine study 
Link 𝑻 = 𝑷(𝒀𝟏 > 𝒀𝟐) 𝑴𝑭 = 𝟐𝑻 − 𝟏 
95% bootstrap 
Confidence interval 
probit 0.55 0.10 (-0.08, 0.26) 
log-log  0.55 0.10 (-0.06, 0.24) 
clog-log (Monte Carlo simulation) 0.54 0.09 (-0.05, 0.26) 









) 0.55 0.09 (-0.08, 0.27) 
𝛿 = 1.749 0.55 0.09 (-0.07, 0.25) 
*Siev (2005) 0.54 0.08 (-0.07,0.23)  
*Poon (2004) 0.55 0.10 (-0.11, 0.30)  
* These values have been directly taken from Siev (2005). 
 
 
Table 3.5. Results of estimated values of MF for the Tacrine study without latent variable 
Link 𝑻 = 𝑷(𝒀𝟏 > 𝒀𝟐) 𝑴𝑭 = 𝟐𝑻 − 𝟏 
95% bootstrap 
Confidence interval 
probit 0.54 0.09 (-0.06, 0.22) 
Logit 0.54 0.08 (-0.07, 0.23) 
log-log 0.54 0.09 (-0.05, 0.22) 
clog-log 0.53 0.07 (-0.07, 0.19) 
*Siev (2005) 0.54 0.08 (-0.07, 0.23)  
*Poon (2004) 0.55 0.10 (-0.11, 0.30)  






3.9 Interpretation of 𝐓 and MF 
Recall that the mitigated fraction was calculated using 𝑀𝐹 = 𝑃(𝑌1 > 𝑌2) −
𝑃(𝑌2 > 𝑌1), where 𝑌1 denotes the non-vaccinated group and 𝑌2 denotes the vaccinated group. 
The interpretation of the mitigated fraction is somewhat not straight forward from a technical 
standpoint. For instance, when the probit model is used, from Table 3.4, 𝑇 = 0.55 (55%) means 
55% of the non-vaccinates are expected to be more severely affected than the vaccinates. Again, 
under the probit model, from Table 3.4, 𝑀𝐹 = 0.1 (10%) indicates that there is a 10% increase 
in the chance that a vaccinate’s disease will be less severe than a non-vaccinate’s disease over 






Chapter 4 - Mitigated fraction for clustered data 
4.1 Theoretical setup for mitigated fraction for clustered data 
Blocking or stratified designs are common in many veterinary and epidemiological 
studies. In many studies, it is impossible to select homogeneous experimental units. When 
experiments are not homogeneous, one method is to group experimental units into sets of nearly 
alike experimental units. Generally, groups of similar experimental units are called blocks 
(Milliken and Johnson, 2009). Each block has a set of experimental units which are similar, such 
as pens of cows, litters of mice, or litters of piglets. The variability between units within a block 
will be less than that of units from different blocks. Moreover, clustering of observations arises 
in a repeated measures study where each subject on which the measurements are collected is 
treated as a cluster.  
First, let us define a generalized linear mixed model that accounts for a cluster effect. Let 
𝑌𝑖𝑡 denote the response for observation 𝑡 in block 𝑖. Let 𝑿𝑖𝑡 = (𝑥1𝑖𝑡,𝑥2𝑖𝑡, … ,𝑥𝑝𝑖𝑡)
𝑇
 denote the 
values of the 𝑝-dimensional vector of explanatory variables for that observation. Let 𝜷 be a p-
dimensional column vector of parameter coefficients. Also, let 𝒛𝑖𝑡 be a 𝑞-dimensional vector of 
covariates associated with a 𝑞-dimensional random column vector of parameter coefficients, 𝒃𝒊.  
Let 𝜋𝑖𝑡𝑗(𝒃𝒊) = 𝑃(𝑌𝑖𝑡 ≤ 𝑗|𝒃𝒊) be the conditional cumulative probability given cluster effect 𝒃𝒊 
and the cumulative probability is typically modeled as,                                                                                          
                         𝐺−1 (𝜋𝑖𝑡𝑗(𝒃𝒊)) = 𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷 −𝒛𝑖𝑡
′ 𝒃𝒊 for 𝑗 = 1,… , 𝐽 − 1                                 (4.1) 
where 𝐺−1 is an arbitrary link function. 
The above model is typically called as cluster-specific model. Following Agresti (2010), a 





′ 𝒃𝒊 + 𝜖𝑖𝑡, 
The above latent variable is a conditional variable based on cluster effect 𝒃𝒊 and the estimation 
of the mitigated fraction requires a marginal latent variable 𝑌𝑖𝑡
∗. 𝑌𝑖𝑡
∗  could easily be derived from a 
marginal model which is typically called a population-averaged model (Agresti and Natarajan, 
2001). 
Let 𝜋𝑖𝑡𝑗 = 𝑃(𝑌𝑖𝑡 ≤ 𝑗)  be marginal cumulative probability which could be derived as follows, 
𝜋𝑖𝑡𝑗 = 𝐸[𝐺(𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷 −𝒛𝑖𝑡
′ 𝒃𝒊)], 
where the expectation is with respect to the distribution of random effect 𝒃𝒊. It could similarly be 
expressed as, 
𝜋𝑖𝑡𝑗 = ∫𝐺(𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷 −𝒛𝑖𝑡
′ 𝒃𝒊) 𝒅𝑭(𝒃𝒊). 
Here, 𝑭 is the distribution of random effects 𝒃𝒊 and 𝑭 is generally assumed to be a Gaussian 
distribution with mean 𝟎  and variance-covariance matrix 𝑫. 




′ 𝒃𝒊) 𝒅𝑭(𝒃𝒊)]. 
Note that we do not normally expect for the right-hand side of the above equation to be 𝛾𝑗 −
𝑿𝑖𝑡
′ 𝜷 with same parameter values as in cluster-specific model. But when identity link, 𝐺−1 = 𝐼, 
is used, it is trivial and  𝜋𝑖𝑡(𝒃𝒊) = 𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷− 𝒛𝑖𝑡
′ 𝒃𝒊. In general, if the conditional cumulative 
probabilities in the cluster-specific model hold with an arbitrary link 𝐺−1 then the marginal 
cumulative probabilities in marginal model will not hold with same link 𝐺−1 (Agresti et al., 
2001). 
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The probit link used for the cluster-specific model, 𝛷−1(𝜋𝑖𝑡(𝒃𝒊)), with Gaussian distribution for 
𝒃𝒊 with mean 𝟎 and covariance matrix 𝑫, gives a marginal probit model with different 
parameters as given as, 
𝜋𝑖𝑡 = 𝛷[(𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷) ∗ 𝑎𝑝(𝑫)], for 𝑗 = 1,2, … , 𝐽 − 1                                               (4.2) 
where 𝑎𝑝(𝑫) = |𝑫𝒛𝑖𝑡𝒛𝑖𝑡
′ + 𝐼|−𝒒/𝟐 with 𝑞 as the dimension of 𝒃𝒊 (Zeger, Liang and Albert, 
1988). 
When the logit link is used for the cluster-specific model, 𝑙𝑜𝑔𝑖𝑡(𝜋𝑖𝑡(𝒃𝒊)), with Gaussian 
distribution for 𝒃𝒊 with mean 𝟎 and covariance matrix 𝑫, the marginal cumulative probabilities 
𝜋𝑖𝑡 do not have a closed-form expression. An approximate expression was discussed in Zeger et 
al. (1988) with the use of Gaussian approximation to logistics function given by, 
𝑙𝑜𝑔𝑖𝑡(𝜋𝑖𝑡) ≈ (𝛾𝑗 − 𝑿𝑖𝑡
′ 𝜷) ∗ 𝑎𝑙(𝑫), for 𝑗 = 1,2, … , 𝐽 − 1                                          (4.3) 
where 𝑎𝑙(𝑫) = |𝑐
2𝑫𝒛𝑖𝑡𝒛𝑖𝑡
′ + 𝐼|−𝒒/𝟐 with 𝑐 = 16√3/15𝜋. 
Having the above general set up for clustered models, let us discuss a simple clustered data 
analysis for a vaccine study with a (generalized) randomized complete block design where two 
treatments (either vaccine or placebo) are assigned to experimental units completely at random 
within each block. Here there is a single factor of treatment type with two levels (vaccine and 
placebo) as the explanatory variable. Let 𝑥𝑖𝑡 denote the explanatory variable as a group indicator 
for an observation where 𝑥𝑖𝑡 = 1  for the placebo group and 𝑥𝑖𝑡 = 0 for the vaccine group. For 
this simple setup 𝑝 = 1 for the single explanatory variable resulting in 𝜷 = 𝛽1, 𝑿𝒊𝒕 = 𝑥𝑖𝑡 and 
𝑞 = 1 for single random block effect with 𝒃𝒊 = 𝑏𝑖, and 𝒛𝑖𝑡
′ = 1. 
For the probit link, the cluster specific model becomes 
𝛷−1 (𝜋𝑖𝑡𝑗(𝑏𝑖)) = 𝛾𝑗 − 𝑥𝑖𝑡𝛽1 − 𝑏𝑖 for 𝑗 = 1,… , 𝐽 − 1.  
Now the marginal model equation (4.2) becomes 
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𝜋𝑖𝑡𝑗 = 𝑃(𝑌𝑖𝑡 ≤ 𝑗) = 𝛷[(𝛾𝑗 −𝑥𝑖𝑡𝛽1) ∗ (1 + 𝜎𝑏
2)−1/2]. 
An underlying normal latent variable 𝑌𝑖𝑡
∗   will be given as 𝑌𝑖𝑡
∗~𝑁 ((1 + 𝜎𝑏
2)−
1
2𝛽1𝑥𝑖𝑡, 1). Let 𝑌1
∗ and 
𝑌2
∗ denote independent underlying latent variables such that when 𝑥𝑖𝑡 = 1 then 𝑌1
∗ for the placebo 
group and when 𝑥𝑖𝑡 = 0 then 𝑌2
∗ for the vaccine group. 
Thus, 𝑌1
∗~𝑁 ((1 + 𝜎𝑏
2)−
1
2𝛽1, 1) and 𝑌2
∗~(0,1). 







) − 1. 
Relationship between mitigated fraction and block variance under probit model 







) − 1}. It can 
clearly be seen from this expression that the argument for the standard normal cdf, 𝛷, depends 
on the value of the block variance. For a fixed value of 𝛽1, when the value of the block variance 
increases, the value for the 𝛷 tends to 0.5, and thus the estimated 𝑀𝐹 tends to 0. When the value 
for 𝑀𝐹 is 0, then there is no severity reduction advantage due to vaccine and thus there will be 
no difference between vaccine and placebo. The figure 1 shows a relationship between mitigated 
fraction and block variance for 𝛽1 = 0.3. Care must be taken when choosing value for block 
variance compared to a given value for 𝛽1 for the simulation study. Table 8 show the central 
coverage probability for different values of block variance with a fixed value of 𝛽1.  
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Figure 4.1. Relationship between mitigated fraction and block variance 
 
For the logit link, the cluster specific model becomes 
𝑙𝑜𝑔𝑖𝑡 (𝜋𝑖𝑡𝑗(𝑏𝑖)) = 𝛾𝑗 − 𝑥𝑖𝑡𝛽1 − 𝑏𝑖 
Now the marginal model comes directly from equation (4.3)  
𝑙𝑜𝑔𝑖𝑡(𝜋𝑖𝑡𝑗) = 𝑙𝑜𝑔𝑖𝑡[𝑃(𝑌𝑖𝑡 ≤ 𝑗)] = [(𝛾𝑗 −𝑥𝑖𝑡𝛽1) ∗ (1 + 𝑐
2𝜎𝑏
2)−1/2]. 









2𝛽1, 1) and 𝑌2
∗~𝑙𝑜𝑔𝑖𝑠𝑡𝑖𝑐(0,1). 
Again, a numerical solution using Monte Carlo simulation methods, discussed in Chapter 3, was 
used for the logistic distribution as the distribution of (𝑌1
∗ − 𝑌2
∗) does not follow a closed form 
distribution. The value of 𝑃(𝑌1
∗ > 𝑌2
∗) was estimated using Monte Carlo simulation method and 





𝑖=1 − 1. 
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4.2 True value for mitigated fraction 
Following the discussion in Section 4.1, the marginal probabilities can be found under 
probit and logit link models. Let 𝜋𝑖𝑗 be the marginal probability for the j
th category for ith group 
(either placebo or vaccine) with 𝑗 = 1,2, … , 𝐽 and 𝑖 = 1,2 (The equation (4.1) and equation (4.2) 
can be used to find the marginal probabilities for probit and logit link models respectively). Now 
𝑇 = 𝑃(𝑌1 > 𝑌2) +
1
2
𝑃(𝑌1 = 𝑌2) can be calculated by 







for 𝑗, 𝑘 = 1,2, … , 𝐽 (Agresti et al., 2017).  
If the true values for 𝜋𝑖𝑗′s are known, then 𝑀𝐹 = 2𝑇 − 1. 
If the true values for 𝜋𝑖𝑗′s  are not known, then the estimated mitigated fraction equals 2?̂? − 1 
with 







where ?̂?1𝑗 and ?̂?2𝑘 are fitted values from the corresponding link function of cumulative 
probability model. And hence the mitigated fraction can be estimated without latent variable 
assumption using the above measure and estimated 𝑀𝐹 equal to 2?̂? − 1. 
4.3 Simulation study 
First define a response variable that comes from the multinomial distribution with a 
random blocking factor, i.e. 
𝑛𝑖𝑡1, 𝑛𝑖𝑡2, … , 𝑛𝑖𝑡𝐽|𝑏𝑖~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑖𝑡, 𝜋𝑖𝑡1
′ , 𝜋𝑖𝑡2
′ , … , 𝜋𝑖𝑡𝐽
′ ). 
• 𝑛𝑖𝑡𝑗 denotes number of observations in category 𝑗 for treatment 𝑡 and block 𝑖 with 
∑ 𝑛𝑖𝑡𝑗 = 𝑁𝑖𝑡
𝐽
𝑗=1 , where the 𝑁𝑖𝑡 is the total number of observations for treatment 𝑡 in block 𝑖. 
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• 𝜋𝑖𝑡𝑗
′  is the probability of 𝑗th category for treatment 𝑡 in cluster 𝑖 with ∑ 𝜋𝑖𝑡𝑗
′ = 1𝐽𝑗=1 . 
• 𝑏𝑖 denotes the block effect for block 𝑖 with 𝑏𝑖~𝑁(0, 𝜎𝑏
2); the number of blocks was set to 8 
for the simulation study.  
• For this simulations study, five ordinal categories (𝑐0, 𝑐1, 𝑐2, 𝑐3 and 𝑐4) were considered in 
the order of increasing severity, i.e. 𝑐0 is the lowest level of the categories and 𝑐4 is the 
highest level of the categories. 
• A single explanatory variable, 𝑥𝑖𝑡, was used as a group indicator with 𝑥𝑖𝑡 = 1 for the control 
group and 𝑥𝑖𝑡 = 0 for the vaccine group. 
The simulation study was conducted using the following model. Let 𝜋𝑖𝑡𝑗 be the cumulative 
probabilities such that 𝜋𝑖𝑡𝑗 = 𝑃(𝑌𝑖𝑡 ≤ 𝑗|𝑥𝑖𝑡) =  𝜋𝑖𝑡1
′ + 𝜋𝑖𝑡2
′ +⋯+ 𝜋𝑖𝑡𝑗
′  with ∑ 𝜋𝑖𝑡𝑗
′ = 1𝐽𝑗=1 . 
The cumulative probability model will be: 
𝜋𝑖𝑡𝑗 = 𝐺(𝜂𝑗), 𝜂𝑗 = 𝛾𝑗 − 𝑥𝑖𝑡𝛽1 − 𝑏𝑖   for 𝑗 = 1,2,3,4. 
where 𝜂𝑗 is the linear predictor, 𝐺 is inverse of an arbitrary link function. 
 
The simulation consists of the following steps: 
1. First, simulate the block effects. Block effects were randomly drawn from a normal 
distribution with a mean of 0 and a particular variance. Different values for the block 
variance were chosen and the values are given in the description under Table 8 and Table 
9. Since there were 8 blocks, 8 block effects were drawn for each simulated data set, with 
each value repeated for each observation within the same block. 
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2. For each block, given value of 𝛾1, 𝛾2, 𝛾3, 𝛾4, 𝛽1, and 𝜎𝑏
2, the linear predictor, 𝜂𝑗 was 
found. The values for 𝛾1, 𝛾2, 𝛾3, 𝛾4, 𝛽1, and 𝜎𝑏
2 used in the simulation study are given in 






′ ) for vaccine and control groups were found based 
on the following model with given a link function. 
𝑃(𝑌𝑖𝑡 ≤ 𝑗|𝑥𝑖𝑡) = 𝐺(𝜂𝑗)  for 𝑗 = 1,2,3,4. 





′ ) can be found in such a way that 
𝜋𝑖𝑡𝑗
′ = 𝜋𝑖𝑡𝑗 − 𝜋𝑖𝑡𝑗−1 for 𝑗 = 2, . . , 𝐽 with 𝜋𝑖𝑡1
′ = 𝜋𝑖𝑡1 and 𝜋𝑖𝑡𝐽 = 1. 





′ , for vaccine and control, independent 
samples containing 100 observations each were generated for the two treatment groups 
respectively (i.e.100 observations for control group and 100 observations for vaccine 
group. 
A total of 10,000 simulated data sets were generated for each parameter setting for a given link 
function. For each data set, a 95% confidence interval for the mitigate fraction was found using 
the bootstrap technique. The simulation results for probit link and logit link function are 
presented in Table 4.1 and Table 4.2 respectively where the true value of 𝑀𝐹 has been calculated 
using the method discussed in Section 4.2.  For a true coverage rate of 0.95, the Monte Carlo 











95% CI for the true 
coverage rate 
0.3 0.01 0.10 0.950 (0.9457, 0.9543) 
0.3 0.1 0.32 0.949 (0.9447, 0.9533) 
0.3 0.2 0.45 0.953 (0.9487, 0.9573) 
0.3 0.3 0.55 0.948 (0.9437, 0.9523) 
0.3 0.6 0.77 0.947 (0.9427, 0.9513) 
0.3 0.9 0.95 0.944 (0.9397, 0.9483) 
The values of (0.01,0.1,0.2,0.3,0.6,0.9) for 𝜎𝑏
2 and 𝛾1 = −1.5, 𝛾2 = −0.3, 𝛾3 = 1, 𝛾4 = 2, and 
𝛽1 = 0.3 are used for this simulation study. 
 
From Table 4.1, it is evident that the latent variable approach using the probit link to calculate 
𝑀𝐹 yields promising results. All, but one, of the 95% CI for the true coverage rate contains the 
true coverage rate (0.95) based on the 10,000 simulations. 
 
 





95% CI for the true 
coverage rate 
0.5 0.1 0.32 0.952 (0.9477, 0.9563) 
0.5 0.5 0.71 0.947 (0.9447, 0.9533) 
0.5 1.5 1.22 0.946 (0.9417, 0.9503) 
The values of (0.1,0.5, 1.5) for 𝜎𝑏
2 and 𝛾1 = −1.5, 𝛾2 = −0.3, 𝛾3 = 1, 𝛾4 = 2, and 𝛽1 = 0.5 are 
used for this simulation study. 
 
From Table 4.2, it is evident that the latent variable approach using the logit link to calculate 𝑀𝐹 
yields promising results. All the 95% CI for the true coverage rate contains the true coverage rate 
(0.95) based on the 10,000 simulations. 
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4.4 Model comparison and model selection. 
Based on the simulation study for clustered data, the probit and logit functions give promising 
results to estimate the mitigated fraction. In order to select the best link function to estimate the 
mitigated fraction, a simulation study was conducted. The best link function will be selected 
based on the percentage of bias-to-true value of the mitigated fraction.  
The simulation consists of the following steps: 





′ , as described in Section 4.3, for 
vaccine and control, independent samples containing 20 observations each were 
generated for the two treatment groups respectively (i.e. 20 observations for control 
group and 20 observations for vaccine group). 
2. Step 1 was repeated and a total of 10,000 simulated data sets were generated for each 
parameter setting for a given link function. For each data set, the mitigated fraction was 
found using the latent variable approach, that is 10,000 estimated mitigated fraction 
values were found using the latent variable approach. 
3. The mean value of the 10,000 estimated mitigated fraction values was found for each link 
function. 
4. The true value of the mitigated fraction was found for each link function using the 
method discussed in Section 4.2. 
5. The bias was found for each link function as follows. 
𝐵𝑖𝑎𝑠 =  𝑚𝑒𝑎𝑛 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 10,000 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝑚𝑖𝑡𝑖𝑔𝑎𝑡𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑣𝑎𝑙𝑢𝑒𝑠
− 𝑡𝑟𝑢𝑒 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑖𝑔𝑡𝑎𝑔𝑒𝑑 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛. 
The simulation results for all link functions are presented in Table 4.3. 
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True Value Bias 
Bias-to-true 
value percentage 
probit 0.25099 0.236504 0.014487 6.13% 
logit  
(Monte Carlo simulation) 
0.164088 0.154322 0.009766 6.33% 
 
 
4.5 Real data analysis 
This example is again from Poon (2004) where five randomized vaccine trials on administering 
the anti-cholinesterase drug tacrine to patients with Alzheimer’s disease were considered. Patients 
receiving tacrine (𝑇) and placebo (𝑃) are, respectively, classified into five categories: ‘very much 
improved’ (𝑐0), ‘minimally improved’ (𝑐1), ‘no change’ (𝑐2), ‘minimally worse’ (𝑐3) and ‘very 
much worse’ (𝑐4). Here ‘𝑐0’ is the clinically best response and ‘𝑐4’ is the worst (order of increasing 
disease severity) and the trials are treated as blocks/clusters. The data is given in Table 4.4 and the 
results are presented in Table 4.5. Whitehead et al. (2001) and Poon (2004) have suggested that in 
each trial, there is a tendency for patients receiving the treatment ‘Tacrine’ to have better responses 
than those receiving placebo. 
As discussed in the Section 4.2, the mitigated fraction can be estimated without using the latent 







     Table 4.4. The data for the clustered Tacrine study 
 Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 
Severity P T P T P T P T P T 
𝒄𝟎 2 4 1 14 7 13 8 21 2 3 
𝒄1 22 23 22 119 16 20 24 106 13 14 
𝒄2 54 45 35 180 17 24 73 175 18 19 
𝒄3 29 22 11 54 10 10 52 62 7 3 
𝒄4 3 2 3 6 3 1 13 17 1 0 
Total 110 96 72 373 53 68 170 381 41 39 
Data source: Poon, W. (2004). A latent normal distribution model for analyzing ordinal responses 
with applications in meta-analysis. Statistics in medicine, 23:2155–2172. 
 
 
Table 4.5. Results of the mitigated fraction for the clustered Tacrine study 
Link 𝑴𝑭 = 𝟐𝑻 − 𝟏 95% bootstrap Confidence interval 
probit 0.1610275 (0.0900, 0.2297) 
Logit (Monte Carlo simulation) 0.1720648 (0.0958, 0.2464) 
 
 
Table 4.6. Results of estimated values for the MF for the Tacrine study without latent variable 
Link 𝑴𝑭 = 𝟐𝑻 − 𝟏 95% bootstrap Confidence interval 
probit 0.1434804 (0.0808, 0.2032) 







Chapter 5 - Bayesian approach for mitigated fraction 
In this chapter, a Bayesian statistical approach will be discussed to estimate the mitigated 
fraction from ordinal response variables. A Bayesian approach seems more natural in medical 
diagnosis studies and pharmaceutical industries. Compared to frequentist methods, the Bayesian 
approach is rather straightforward in model parameter estimation and results interpretation, 
especially for models with random effects and non-normal responses (Generalized linear mixed 
models). Agresti et al. (2001) stated that the Bayesian approach is advantageous specifically for 
clustered ordinal responses since the frequentist approach appears to suffer with cluster-specific 
and population-average models when it comes to the generalized linear mixed models. The 
parameter estimation through the Bayesian approach is computationally advantageous as the 
estimation directly coming from posterior samples when compared to the maximum likelihood 
estimation which leads to computational awkwardness for high-dimensional maximization. 
Albert and Chib (1993) presented a Bayesian approach for binary and ordinal response 
data models using the data augmentation approach via an underlying latent continuous variable. 
Albert and Chib (1993) briefly mentioned possible extensions from binary data to ordered 
categorical data. They proposed an ordinal probit model in a Bayesian framework using the 
Gibbs sampling technique for generating posterior samples for parameters. Cowles (1996) 
discussed a hybrid Gibbs/Metropolis–Hasting (MH) sampling scheme for accelerating MCMC 
convergence for models like the ordered probit model. Johnson et al. (1999) discussed a detailed 





5.1 Some notations related to Bayesian analysis 
In this chapter of the Bayesian analysis, most of terms and notation follow closely to 
those found in Gelman, Carlin, Stern, Dunson, Vehtari, and Rubin (2013). Consistent with 
Gelman et al. (2013), the terms ‘distribution’ and ‘density’ are interchangeably used in this 
chapter. The same notation will be used for continuous density functions and discrete probability 
mass functions.  
Let 𝑝(∙ | ∙) be a function which denotes a conditional probability density with the arguments 
determined by the context; 𝑝(∙) denotes a marginal probability distribution. To avoid confusion, 
in this chapter the notation 𝑃𝑟(∙) will be used for the probability of an event whereas the 
standard notation 𝑃(∙) has been used for the probability of an event in all other chapters Gelman 
et al. (2013). 
 
Bayes’ rule 
With reference to Gelman et al. (2013), the joint probability density (mass) function of 𝜃 
and 𝑦 can be written as a product of two density (mass) functions that are often referred to as the 
prior distribution 𝑝(𝜃) and the sampling distribution (or data distribution) 𝑝(𝑦|𝜃), respectively. 
Simply conditioning on the known value of the data 𝑦, using the Bayes’ rule of conditional 







,                                                                                                   (5.1) 
where 𝑝(𝑦) = ∫ 𝑝(𝜃)𝑝(𝑦|𝜃)𝑑𝜃  (or 𝑝(𝑦) = ∑ 𝑝(𝜃)𝑝(𝑦|𝜃)𝜃  in case of discrete 𝜃, and the sum is 
over all possible values of 𝜃). The factor 𝑝(𝑦) in the expression (5.1) does not depend on 𝜃 and, 
with fixed 𝑦, can thus be considered a constant, yielding the unnormalized posterior density, 
which is the right side of the expression (5.2): 
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𝑝(𝜃|𝑦) ∝ 𝑝(𝜃)𝑝(𝑦|𝜃).                                                                                                   (5.2) 
The second term in the expression (5.2), 𝑝(𝑦|𝜃), is considered as a function of 𝜃, not 𝑦 (Gelman 
et al., 2013).  
 
Likelihood 
Likelihood contributes significantly to the posterior inferences. Following the Bayes’ 
rule, the data 𝑦 has the contribution to the posterior inference (5.2) only through 𝑝(𝑦|𝜃), which, 
when regarded as a function of 𝜃, for fixed 𝑦, is called the likelihood function (Gelman et al., 
2013). 
 
5.2 The Gibbs Sampler 
The Gibbs sampler is a Markov chain Monte Carlo (MCMC) algorithm. The Gibbs 
sampler is used as a computational technique in the calculation of marginal distribution of the 
parameters of interest, given a set of conditional distributions. In the Bayesian context, it is used 
to obtain marginal posterior distribution of the parameters of interest. 
Let 𝜃 = (𝜃1, 𝜃2, … , 𝜃𝑑) be the vector of posterior distribution parameters of interest. One is 
interested in generating samples from the posterior distribution 𝑝(𝜃|𝑦). The primary goal is to 
determine the marginal distributions, 𝑝(𝜃1), 𝑝(𝜃2),… , 𝑝(𝜃𝑑) (Chipman and Hamada, 1996). 
When the full conditional distributions 𝑝(𝜃𝑘|{𝜃𝑗 , 𝑗 ≠ 𝑘, 𝑗 = 1,2, … , 𝑑}) are available, then the 





To generate sample from 𝑝(𝜃|𝑦), the Gibbs sampler can be implemented as follows: 




, … , 𝜃𝑑
(0)
). 
Repeat the following procedure until convergence for 𝑟 =  1, 2, . … 
Generate 𝜃1
(𝑟)
 from 𝑝(𝜃1| 𝜃2




 from 𝑝(𝜃2| 𝜃1
(𝑟−1), 𝜃3







 from 𝑝(𝜃𝑑| 𝜃1
(𝑟−1), 𝜃2
(𝑟−1), … , 𝜃𝑑−1
(𝑟−1), 𝑦). 
Following Geman and Geman (1984) and Chipman et al. (1996), when 𝑟 approaches infinity, the 




, … , 𝜃𝑑
(𝑟)
) converges in distribution to 
a sample from the joint distribution. Consequently, any subset of the random variables, 𝜃 =
(𝜃1, 𝜃2, … , 𝜃𝑑), can be viewed as a sample from the appropriate marginal distribution, i.e. 
𝑝(𝜃1), 𝑝(𝜃2), … , 𝑝(𝜃𝑑) (Chipman and Hamada, 1996). 
Following Chipman et al. (1996), there are several different strategies for implementing 
the Gibbs sampler for obtaining posterior samples of parameters. All the different strategies are 
centralized to obtain a representative sample of the posterior. One of the important factors is the 
number of iterations required to remove the effect of starting values of the parameters of interest. 
The number of iterations required to remove the effect of starting values are called burn-in time 
(Chipman et al., 1996). Generally, the burn-in time is quite large in such a way that it is most 
efficient to use many values taken from a single long run of the Gibbs sampler. The length of the 
burn-in time can be determined by comparing several chains using different starting values and 
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checking the convergency of the simulated sequence. Several other issues of obtaining a 
representative sample can be found in Chipman et al. (1996). 
5.3 Bayesian probit model 
First, a Bayesian probit model is considered to estimate the mitigated fraction. The 
implementation of this Bayesian probit model for ordinal data follows closely to those found in 
Albert et al. (1993) and Chipman et al. (1996). Let 𝒀 = (𝑌1,, … , 𝑌𝑛) denote the observed vector 
of the responses for all individuals, 𝑿𝒊
′ = (𝑥𝑖1, 𝑥𝑖2, … , 𝑥𝑖𝑝) is a 𝑝-dimensional vector of 
explanatory variables, and 𝜷 = (𝛽1, 𝛽2, … , 𝛽𝑝)
′
 is a 𝑝-dimensional vector of parameters.   
The likelihood function for 𝒀 given 𝜷, 𝜸  will be 









where 𝛷 is the standard norm cdf, and 𝐼(∙) indicates an indicator function. 
The unknown parameters are the regression vector 𝜷 and the vector of cutoffs 𝜸 =
 (𝛾1, … , 𝛾𝐽−1).  
As discussed in Chapter 2, under a probit model, a continuous latent variable 𝑌𝑖
∗ satisfies 
an ordinary regression model 𝑌𝑖
∗  = 𝑿𝒊
′𝜷 + 𝜖𝑖 where 𝜖𝑖 follows a standard normal cdf. The latent 
normal continuous variable 𝑌𝑖
∗ is distributed as 𝑁(𝑿𝒊
′𝜷, 1). If the model is parameterized using 
the latent data 𝒀∗  = (𝑌1
∗ , … , 𝑌𝑛
∗ ) along with the parameters 𝜷 and 𝛄, then the likelihood, as a 
function of this entire set of unknown parameters and latent data is expressed as 
𝐿(𝒀|𝜷, 𝜸, 𝒀∗) =∏𝛷(𝑌𝑖
∗ − 𝑿𝒊









For the rest of this chapter, the vector notations will used with 𝒀, 𝒀∗, 𝜷, and 𝜸 as vectors 
of lengths 𝑛, 𝑛, 𝑝, and 𝐽 −  1, respectively, and 𝑿 = (𝑿1
′ , 𝑿2
′ , … , 𝑿𝑛
′ )′ denoting a full rank 𝑛 × 𝑝 
design matrix. 
Independent priors can be assumed for the parameters 𝜷 and 𝜸. The joint prior distribution can 
be written as 𝑝 (𝜷, 𝜸)  =  𝑝 (𝜸) 𝑝 (𝜷). The priors can be vague (flat) priors for both 𝜷 and 𝜸. 
Also, normal priors can be used for 𝜷 and 𝜸 as follows: a prior for 𝜷 will be given as  
𝜷~ 𝑁(𝟎, 𝛴𝛽) and for 𝜸 will be given as 𝜸~ 𝑁(𝟎,𝑫), where 𝑫 is a diagonal and 𝜸 is restricted so 
that 𝛾1 < 𝛾2 <,… , 𝛾𝐽−1. Typically, 𝛴𝜷 also diagonal, with 𝛴𝜷 = 𝜎𝜷
2𝐼.  
The joint posterior density of 𝜷, 𝜸, and 𝐘∗ will be written as follows: 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) = 𝐶 𝑝(𝒀|𝜷, 𝜸, 𝒀∗)𝑝(𝜷, 𝜸, 𝒀∗) 
where 𝐶 is a proportionality constant. 
Following the expression (5.2), the joint posterior density is given, up to a proportionality 
constant, by 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝(𝒀|𝜷, 𝜸, 𝒀∗)𝑝(𝜷, 𝜸, 𝒀∗) 
Using the fact 𝑝(𝜷, 𝜸, 𝒀∗) = 𝑝(𝒀∗|𝜷, 𝜸)𝑝(𝜷, 𝜸), 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝(𝒀|𝜷, 𝜸, 𝒀∗)𝑝(𝒀∗|𝜷, 𝜸)𝑝(𝜷, 𝜸). 
For any given 𝒀∗, 𝒀 is independent of 𝜷, and hence 𝑝(𝒀|𝜷, 𝛾, 𝒀∗) = 𝑝(𝒀|𝜸, 𝒀∗), 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝(𝒀|𝜸, 𝒀∗)𝑝(𝒀∗|𝜷, 𝜸)𝑝(𝜷, 𝜸) 
The distribution of 𝒀∗ given 𝜷 and 𝜸 does not depend on 𝜸, and hence 𝑝(𝒀∗|𝜷, 𝜸) = 𝑝(𝒀∗|𝜷). 
This is follows that the only dependence of 𝒀∗ on 𝜸 is through 𝒀. 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝(𝒀|𝜸, 𝒀∗)𝑝(𝒀∗|𝜷)𝑝(𝜷, 𝜸). 
Having assumed independent priors for 𝜷 and 𝜸, 𝑝 (𝜷, 𝜸) =  𝑝 (𝜸)𝑝 (𝜷). 
The joint posterior density of 𝜷, 𝜸, and 𝒀∗ given by 
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𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝(𝒀|𝜸, 𝒀∗)𝑝(𝒀∗|𝜷)𝑝 (𝜸) 𝑝 (𝜷) 
Here the form of 𝑝(𝒀∗|𝜷) will be determined by the link function. Under a probit link function, 
𝑝(𝒀∗|𝜷) = 𝑁(𝑿𝜷, 𝑰). 
Now the joint posterior distribution under the probit model becomes: 
𝑝(𝜷, 𝜸, 𝒀∗|𝒀) ∝  𝑝 (𝜸) 𝑝 (𝜷) ∏𝛷(𝑌𝑖
∗ − 𝑿𝒊








with the form of 𝜙, i.e. the standard normal cdf, and then joint posterior distribution under the 
probit model will be 









∗  ≤ 𝛾𝑗)}]. 
Using flat (highly diffuse) priors for 𝜷 and 𝜸, with 𝑝(𝜷) ∝ 1 and 𝑝(𝜸) ∝ 1, the joint posterior 
density is given, up to a proportionality constant, by 












∗  ≤ 𝛾𝑗)}]
𝑛
𝑖=1
      (5.3) 
Gibbs sampler will be used to estimate the parameters since full conditional distributions 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀),  𝑝(𝒀∗|𝜸, 𝜷, 𝒀) and 𝑝(𝜸|𝒀∗, 𝜷, 𝒀) can be constructed. 
The full conditional distributions of 𝜷,𝜸 and 𝒀∗ can be expressed as following. 
1. The full conditional posterior distribution of 𝜷 given on 𝜸, 𝒀∗ and 𝒀 is 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  𝑝(𝜷)𝑝(𝒀∗|𝜷). 
With 𝑝(𝜷) ∝ 1 and 𝑝(𝒀∗|𝜷) = 𝑁(𝑿𝜷, 𝑰), this becomes 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  1 ∗ 𝑁(𝑿𝜷, 𝑰). 
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Here, the right hand side of the above expression needed to be modified in such a way that the 
distribution of 𝜷 given 𝜸, 𝒀∗, 𝒀 will be in closed form. 
                      𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  exp (
−1
2
∥ 𝒀∗ −𝑿𝜷 ∥𝟐) 
Let ?̂? = (𝑿′𝑿)−1𝑿′𝒀∗, and now 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  exp (
−1
2
∥ 𝒀∗ − 𝑿?̂? + 𝑿?̂? − 𝑿𝜷 ∥𝟐) 
Since ∥ 𝒀∗ − 𝑿′?̂? ∥𝟐 does not depend on 𝜷, and having zero for cross of product of 
(𝒀∗ − 𝑿?̂?)
′
 and (𝑿?̂? − 𝑿𝜷), then 
        𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  exp (
−1
2
∥ 𝑿?̂? − 𝑿𝜷 ∥𝟐) 





(𝑿′𝑿)(𝜷 − ?̂?)]) 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  𝑀𝑉𝑁𝑝(?̂?, (𝑿
′𝑿)−1)    
where ?̂? = (𝑿′𝑿)−1𝑿′𝒀∗. 
2. The full conditional posterior distribution of 𝒀∗ given on 𝜸, 𝜷 and 𝒀 is 
𝑝(𝒀∗|𝜸, 𝜷, 𝒀) ∝  𝑝(𝒀∗|𝜷)𝑝(𝒀|𝒀∗, 𝜸) 
      𝑝(𝒀∗|𝜸, 𝜷, 𝒀) ∝  𝑁(𝑿𝜷, 𝑰) ∗ 𝑝(𝒀|𝒀∗, 𝜸) 
The full conditional posterior distribution of 𝑌1
∗, … , 𝑌𝑛
∗ are independent with 
𝑝(𝑌𝑖
∗|𝜸, 𝜷, 𝑌𝑖 = 𝑗) ∝∏𝑁(𝑿𝒊
′𝜷, 1)𝐼(𝛾𝑗−1 < 𝑌𝑖




It is an independent truncated normal distribution with current values of the category cutoffs. 
3. The posterior distribution of 𝜸 given on 𝒀∗ , 𝜷 and 𝒀 is 
𝑝(𝜸|𝒀∗, 𝜷, 𝒀) ∝  𝑓(𝜸)𝑝(𝒀|𝒀∗, 𝜸) 
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It is to be noted that the above expression is a function of 𝛾𝑗 and the summation comes with only 
two components of 𝛾𝑗 as 1(𝑌𝑖 = 𝑗)𝐼(𝛾𝑗−1 < 𝑌𝑖
∗  ≤ 𝛾𝑗) and 1(𝑌𝑖 = 𝑗 + 1)𝐼(𝛾𝑗 < 𝑌𝑖
∗  ≤ 𝛾𝑗+1). 
Thus, the full conditional posterior distribution of 𝛾𝑗 given 𝒀
∗, 𝜷, 𝒀 and {𝛾𝑘, 𝑘 ≠ 𝑗} is given, up 
to a proportionality constant, by  
𝑝(𝛾𝑗|𝒀
∗, 𝛾𝑘, 𝜷, 𝒀) ∝  ∏[1(𝑌𝑖 = 𝑗)𝐼(𝛾𝑗−1 < 𝑌𝑖
∗  ≤ 𝛾𝑗) + 1(𝑌𝑖 = 𝑗 + 1)𝐼(𝛾𝑗 < 𝑌𝑖








∗: 𝑌𝑖 = 𝑗} , 𝛾𝑗−1} ,𝑚𝑖𝑛 {min
𝑖
{𝑌𝑖
∗: 𝑌𝑖 = 𝑗 + 1} , 𝛾𝑗+1}] 
 
5.4 Alternative priors for 𝜸 and  𝜷 - Normal prior for 𝜸 and  𝜷 
5.4.1 A normal prior for 𝜸 
Alternatively, a normal prior for 𝜸 can be assumed as,  𝜸~ 𝑁(𝟎,𝑫), where 𝑫 is a 
diagonal and 𝜸 is restricted so that 𝛾1 < 𝛾2 <,… , 𝛾𝐽−1. Appropriate values will be chosen for the 
hyper parameters 𝑫. 
The full conditional posterior distribution of 𝜸 given 𝒀∗ , 𝜷, and 𝒀 is given, up to a 
proportionality constant, by  
𝑝(𝜸|𝒀∗, 𝜷, 𝒀) ∝  𝑝(𝜸)𝑝(𝒀|𝒀∗, 𝜸) 
The full conditional posterior distribution of 𝛾𝑗 given 𝒀
∗ , 𝜷, 𝒀 and {𝛾𝑘, 𝑘 ≠ 𝑗} is given, up to a 
proportionality constant, by  
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𝑝(𝛾𝑗|𝒀
∗, 𝛾𝑘, 𝜷, 𝒀)
∝ 𝑁 (0, 𝜎𝛾𝑗
2  )  ∏[1(𝑌𝑖 = 𝑗)𝐼(𝛾𝑗−1 < 𝑌𝑖




∗  ≤ 𝛾𝑗+1)] 
𝑝(𝛾𝑗|𝒀
∗, 𝛾𝑘, 𝜷, 𝒀) ∝ 𝑁 (0, 𝜎𝛾𝑗
2  ) [𝑚𝑎𝑥 {max
𝑖
{𝑌𝑖
∗: 𝑌𝑖 = 𝑗} , 𝛾𝑗−1} , 𝑚𝑖𝑛 {min
𝑖
{𝑌𝑖
∗: 𝑌𝑖 = 𝑗 + 1} , 𝛾𝑗+1}] 
Therefor the full conditional posterior distribution of 𝛾𝑗 given 𝒀
∗ , 𝜷, 𝒀 and {𝛾𝑘 , 𝑘 ≠ 𝑗} 




𝑗} , 𝛾𝑗−1} ,𝑚𝑖𝑛 {𝑚𝑖𝑛
𝑖
{𝑌𝑖
∗: 𝑌𝑖 = 𝑗 + 1} , 𝛾𝑗+1}]. 
 
5.4.2 A normal prior for 𝜷 
Alternatively, a normal prior for 𝜷, 𝜷~ 𝑁(𝟎,  𝛴𝛽), typically, 𝛴𝜷 also diagonal, with 𝛴𝜷 =
𝜎𝜷
2𝐼.  
The full conditional posterior distribution of 𝜷 given 𝒀∗, 𝜷, 𝜸 and 𝒀 is given, up to a 
proportionality constant, by  
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  𝑝(𝜷)𝑝(𝒀∗|𝜷). 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  𝑁(𝟎,  𝛴𝛽)𝑁(𝑿𝜷,  𝑰). 
𝑝(𝜷|𝜸, 𝒀∗, 𝒀) ∝  𝑀𝑉𝑁𝑝 (?̂?, (𝜮𝜷
−𝟏 + 𝑿′𝑿)
−1
)     







5.5 Estimating the mitigated fraction for two independent groups using Bayesian 
estimation 
As described in Chapter 3 for estimating the mitigated fraction for two independent 
groups, there is a single factor of treatment type with two levels (vaccine and control) as an 
explanatory variable. Let 𝑥1 denote the explanatory variable as a group indicator for an 
observation, where 𝑥1 = 1 for the control group and 𝑥1 = 0 for the vaccine group. Also, let 𝑌 
denote an independent ordinal random variable with 𝐽 categories. The cumulative probability 
model will be: 
𝜋𝑗 = 𝐺(𝜂𝑗), 𝜂𝑗 = 𝛾𝑗 − 𝛽1𝑥1 for  𝑗 = 1,… , 𝐽 − 1, 
where 𝜂𝑗 is the linear predictor, 𝐺 is inverse of an arbitrary link function, and                         
𝜋𝑗 = 𝑃(𝑌 ≤ 𝑗|𝑥1) = ?̃?1 +⋯+ ?̃?𝑗 with ∑ ?̃?𝑗 = 1
𝐽
𝑗=1  are cumulative probabilities. 
For this analysis of estimating the mitigated fraction using the Bayesian approach, a non-
informative normal prior for 𝜸 and 𝜷. Since there is only one explanatory variable, 𝜷 = (𝛽0, 𝛽1). 
Since the inclusion of 𝛽0 in the regression model, appropriate identification constraint has been 
set as 𝛾1 = 0 and 𝜎𝜖
2 = 1. For each 𝛾𝑗, a non-informative normal prior such that 
𝛾𝑗~𝑁(0,10
6), 𝑗 = 2,3,4 was used. For each 𝛽𝑘, a non-informative normal prior such that 
𝛽𝑘~𝑁(0,10
6), 𝑘 = 1,2 was used. Markov chain Monte Carlo (MCMC) methods of Gibbs 
sampling was implemented to make the inferences for (𝛾2, 𝛾3, 𝛾4, 𝛽1) from the posterior 
distribution. Once the 𝛾2, 𝛾3, 𝛾4, 𝜷 are found from Bayesian approach, estimated 𝑀𝐹 will be as: 
      - with latent variable: 𝑀𝐹 = 2𝑇 − 1 = 2 ∗ 𝛷 (
𝛽1
√2
) − 1. 
- without latent variable: 2?̂? − 1 = 2∑∑ ?̂?1𝑗?̂?2𝑘 +
1
2
∑ ?̂?1𝑗?̂?2𝑘𝑗=𝑘 − 1𝑗>𝑘 . 
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where ?̂?1𝑗 and ?̂?2𝑘 - fitted values can be from the corresponding link function of cumulative 
probability model. 
All of the Bayesian analyses were performed using chains of 50 000 samples, of which the first 
half (i.e. 25,000) was treated as burn-in time and were removed to find a representative samples 
for all parameters. Also, convergence of parameters has been assessed by plotting the simulated 
sequences of the parameters.  
 
5.6 Bayesian approach for the Tacrine study 
The Bayesian approach was applied to estimate the mitigated for the Tacrine study. The 
data is used from Table 5 in Chapter 3. Mitigated fraction was estimated using latent variable 
approach discussed in Section 5.4, and without using the latent variable discussed in Section 3.5. 
The analysis results are presented in the Table 5.1.  
 
 
Table 5.1. Bayesian results of estimated 𝑴𝑭 for the Tacrine study 
Link 𝑻 = 𝑷(𝒀𝟏 > 𝒀𝟐) 𝑴𝑭 = 𝟐𝑻 − 𝟏 
Probit (with latent variable) 0.55 0.1 





Chapter 6 - Conclusion and Discussion 
 This dissertation study may be of great interest to animal health companies and 
associated government agencies. This work is really filling the gap of estimation of the mitigated 
fraction for disease severity when the outcome variable is ordinal, especially when observations 
are clustered. This work focuses on developing methods to estimate the mitigated fraction for 
ordinal data with a parametric approach assuming a generalized linear mixed model (GLMM). 
Ordinal outcomes in terms of measuring disease severity are widely popular in the areas of 
veterinary medicines and epidemiological fields. Currently, the USDA’s Center for Veterinary 
Biologics (CVB) recommends a form of the mitigated fraction which can be calculated when the 
disease severity is graded by some continuous measure or by some discrete assessment resulting 
in unambiguous ranks. Considering the growing interest in the measure of disease severity for 
ordinal outcomes, the development of methods to estimate the mitigated from ordinal data is of 
utmost importance. Two different approaches were discussed to estimate the mitigated fraction: 
one with the frequentist approach and another one with the Bayesian approach. Based on our 
simulation results in Chapters 3 and Chapter 4, our latent variable approach gives promising 
results to estimate the mitigated fraction for ordinal data under different link functions. 
Especially, the probit link gives the best option to estimate the mitigated fraction based on the 
bias-to-true-value comparison. Also, the probit link gives a straightforward (i.e. closed form) 
solution for estimating the mitigated fraction in all situations of CRD and RCBD. 
In Chapter 3 and Chapter 4, methods were discussed to estimate the mitigated fraction for 
two independent groups in a CRD and RCBD setup, respectively. Our study focused on settings 
where an experiment is performed to estimate the mitigated fraction involving two treatments 
such as vaccine and placebo. Under our proposed method, an extension can easily be made to the 
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cases where more than two independent treatment groups are simultaneously compared to a 
placebo using appropriate usage of dummy variables as group indicators. Another extension that 
can easily be made is the inclusion of multiple random effects which can simply be included in 
the linear predictor of the cumulative link model (4.1). 
The proposed method using the latent variable approach can be used to estimate the 
mitigated fraction while adjusting for other explanatory variables such as age, gender, and 
weight of the experimental units. Since many experimental studies on vaccine trials have their 
interest in measuring the efficacy of vaccine based on explanatory variables, our proposed 
method is a powerful approach to estimate the mitigated fraction while accounting for other 
explanatory variables.   
It is very important to note that under the latent variable construction, it was assumed that 
the model holds when an underlying continuous response has the usual regression model 
structure with a constant variance. In that case, the latent response at different explanatory 
variable values differs in terms of location but not dispersion of the latent variables. But, by 
using the latent variable approach, the dispersion of the latent variable still can be handled in 
terms of estimating the mitigated fraction. If the distribution of the latent response at different 
predictor values differs in terms of both location and dispersion, following McCuullagh (1980), a 
general version of the cumulative link model can be written as 




                                                           (6.1) 
The denominator in the right-hand side of the model (6.1) contains the scale parameters 𝛾 that 
describes how the dispersion depends on 𝑿. The latent variable for the above model (6.1) can be 
given as 𝑌𝑖
∗ = 𝜷′𝑿𝑖 + exp (𝛾
′𝑿𝑖)𝜖𝑖. In our ordinary cumulative link model used in this 
dissertation is a special case of the model (6.1) with 𝛾 = 0 (Agresti, 2010). Let us consider the 
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situation from Chapter 3 where an experiment involving two treatments such as vaccine and 
placebo to estimate the mitigated fraction. For this situation, the model (6.1) reduces to                                         
𝐺−1[𝑃(𝑌 ≤ 𝑗|𝑥1)] =
𝛼𝑗−𝛽1𝑥1
exp (𝛾′𝑥1)
, and the latent variable with dispersion effect 𝛾 for this situation 
can be written as  𝑌∗ = 𝛽1𝑥1+ exp(𝛾𝑥1) 𝜖. Under the probit model, 𝑌
∗ follows a normal 
distribution, i.e. 𝑌∗~𝑁(𝛽1𝑥1, exp(𝛾𝑥1)). Letting 𝑌1
∗ and 𝑌2
∗ are the two independent continues 
latent random variables such that 𝑌1
∗ for control group when 𝑥1 = 1 and  𝑌2
∗ for vaccine group 
when 𝑥1 = 0. Then 𝑌1
∗ and 𝑌2




∗~𝑁(0,1). And hence it immediately follows that the mitigated fraction will be equal to 
2 ∗ 𝛷 (
𝛽1
√1+exp(𝛾)2
) − 1, i.e. 𝑀𝐹 = 2 ∗ 𝛷 (
𝛽1
√1+exp(𝛾)2
) − 1. 
Future work 
One of the problems in vaccine studies is that usually most of the subjects do not become 
infected. In this situation, the resulting data contain many observations that are zero, and the 
outcomes are generally referred to as the zero-inflation problem. In this situation, a different 
approach will be recommended where it will allow cumulative models of ordinal data to model 
the distribution of ordinal outcomes more accurately when most of the subjects do not become 
infected. In the event of zero-inflation problem, a zero-inflated model needs to be considered to 
explicitly model the zero inflation, and to model the cumulative probabilities with the 
relationship of possible predictors. 
Let 𝑌𝑖 denote the ordinal response for observation 𝑖, 𝑖 = 1,2, … , 𝑛 with levels 0,1,2, … , 𝐽. A 
multinomial distribution for 𝑌𝑖 will be 
𝑌𝑖~𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙(1, ?̃?0, ?̃?1, … , ?̃?𝐽) 
where ?̃?𝑗 is the probability of a response falls into the 𝑗




Let 𝜃 = ?̃?0, ?̃?1, … , ?̃?𝐽, and a zero-inflated model describes a latent mixture of two populations, 
𝑝(𝑌𝑖|𝜃, 𝑧𝑖) = 𝑧𝑖𝕀{𝑦𝑖 = 0} + (1 − 𝑧𝑖)𝑀𝑢𝑙𝑡𝑖𝑛𝑜𝑚𝑖𝑎𝑙(1, 𝜃) 
where 𝑧𝑖 = 0 or 1 and 𝑧𝑖|𝜔~𝑖𝑖𝑑 𝐵𝑒𝑟𝑛𝑜𝑙𝑙𝑖(𝜔) with 𝜔 as the population mixture parameter. 
When it comes to estimating the mitigated fraction for clustered ordinal data, the 
marginal model is easily be tractable for the probit model and the logit model. However, it is to 
be noted that there is no clear way to get a marginal model when log-log or clog-log link is used 
for cluster-specific model with Gaussian distribution with mean 𝟎 and covariance matrix 𝑫 for 
random effects 𝒃𝒊. However, the clog-log link used for cluster-specific model with log-gamma 
distribution for random effects 𝒃𝒊, the resulting marginal likelihood has a closed form (Thomas, 
1966).  
In this dissertation, the Bayesian approach was discussed only under the probit model. A 
comprehensive Bayesian approach needs to be implemented to estimate the mitigated fraction 
with other link functions such as logit, log-log, and clog-log. Under the probit model, Gibbs 
sampling was used to estimate the parameters from the posterior distribution since the full 
conditional distributions of the parameters were in closed form distributions. But under the logit, 
log-log, and clog-log link function, the full conditional distributions of the parameters will not be 
in closed form distributions and thus Gibbs sampling will not be able to apply. In this situation, 
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Appendix A - R code 












treatment = rep( c(rep("trt", times = c), rep("con", times = c))) 
dat = data.frame(treatment) 
#View(dat) 
for(j in 1:(nu_trt*c)){ 
  mlog_odds[j] =  (alpha1[j]-b1*(dat$treatment[j] == "con")) 
} 
mcumproprobit=pnorm(mlog_odds) 
#cumproplogit = plogis(log_odds) 
mcell_pro=mcumproprobit 
for(j in 2:(nu_trt*c)){ 
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for(j in 1:length(p)){ 
  for(k in 1:length(v)){ 
    if(j==k){ 
      alpha=alpha+0.5*p[j]*v[k] 
    } 
    else if(j>k){ 
      alpha=alpha+p[j]*v[k] 
    } 





















for(k in 1:simN){ 
  ###probit model confidence interval 
  for(j in 1:(nu_trt*c)){ 
    log_odds[j] =  alpha1[j]-b1*(dat$treatment[j] == "con")    
  } 
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  cumproprobit=pnorm(log_odds) 
  #cumproplogit = plogis(log_odds) 
  cell_pro=cumproprobit 
  for(j in 2:(nu_trt*c)){ 
    cell_pro[j]=cumproprobit[j]-cumproprobit[j-1] 
  } 
  cell_pro[seq(1,nu_trt*c,by=c)]=cumproprobit[seq(1,nu_trt*c,by=c)] 
  dat$cumpro=cumproprobit 
  dat$celpro=cell_pro 
  #View(dat) 
 fi=seq(1,(nu_trt*c-c+1), by=c) 
  y=rep(0,nu_trt*c) 
  for(i in fi ){ 
    #rmultinom(1, size = 110, prob = dat$celpro[i:(i+4)]) 
    #checkcell[i:(i+4)]=dat$celpro[i:(i+4)] 
    y[i:(i+4)]= rmultinom(1, size = size, prob = dat$celpro[i:(i+4)]) 
  } 
  dat$y=y 
  #View(dat) 
  #write.csv(dat, "ordinalsimulation2.csv", col.names = TRUE, row.names = FALSE) 
  #size = 20# 
  #ya=rep(0,size*nu_trt) 
  trt_t=rep(0,size*nu_trt) 
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  #m=c(1,11) 
  xt=1 
  #i=11 
    severity <- c(1,2,3,4,5) 
    trt=dat$y[1:c] 
    con=dat$y[(c+1):(c*nu_trt)] 
    yb <- factor(c(rep(severity, con), 
                   rep(severity, trt)), levels = severity) 
    trt_t[xt:(xt+(size-1))]=1 
    trt_t[((xt+(size-1))+1):(((xt+(size-1))+1)+(size-1))]=0 
  newdata=data.frame(trt_t,yb) 
  #View(newdata) 
  y=factor(newdata$yb) 
  trt=newdata$trt_t 
 # blk=newdata$blk 
  ## Cumulative link mixed model with two random terms: 
  #probit.m <- clmm(y ~ trt + (1|blk),  link = "probit",threshold = "equidistant") 
  probit.mm <- clm(y ~ trt,  link = "probit") 
  summary(probit.mm) 
  betap=tail(coef(probit.mm),n=1) 
  alpha=pnorm(betap/sqrt(2),0,1) 
  MF=2*alpha-1 
  print(MF) 
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  ###probit model confidence interval 
  #library(bootstrap) 
  #library(boot) 
  theta.hat=function(d,i) 
  { 
    yn<<-factor(d$yb[i]) 
    xn<<-d$trt_t[i] 
    probit.m <- clm(yn ~ xn ,  link = "probit") 
    betap=tail(coef(probit.m),n=1) 
    MF=2*pnorm(betap/sqrt(2),0,1)-1 
  } 
  oboot=boot(data=newdata,statistic=theta.hat, R=5000) 
  BCa.probit=boot.ci(oboot,conf=.95,type="bca") 
  simCI.probit[k,]=BCa.probit$bca[4:5] 
  if(true>=simCI.probit[k,1] && true<=simCI.probit[k,2]){ 
    count.probit=count.probit+1} 




















treatment = rep( c(rep("trt", times = c), rep("con", times = c))) 
dat = data.frame(treatment) 
#View(dat) 
for(j in 1:(nu_trt*c)){ 
  mlog_odds[j] =  (alpha1[j]-b1*(dat$treatment[j] == "con")) 
} 
mcumproprobit=plogis(mlog_odds) 
#cumproplogit = plogis(log_odds) 
mcell_pro=mcumproprobit 
for(j in 2:(nu_trt*c)){ 













for(j in 1:length(p)){ 
  for(k in 1:length(v)){ 
    if(j==k){ 
      alpha=alpha+0.5*p[j]*v[k] 
    } 
    else if(j>k){ 
      alpha=alpha+p[j]*v[k] 
    } 





















for(k in 1:simN){ 
  ###probit model confidence interval 
  for(j in 1:(nu_trt*c)){ 
    log_odds[j] =  alpha1[j]-b1*(dat$treatment[j] == "con")    
  } 
  cumproprobit=plogis(log_odds) 
  #cumproplogit = plogis(log_odds) 
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  cell_pro=cumproprobit  
  for(j in 2:(nu_trt*c)){ 
    cell_pro[j]=cumproprobit[j]-cumproprobit[j-1] 
  } 
  cell_pro[seq(1,nu_trt*c,by=c)]=cumproprobit[seq(1,nu_trt*c,by=c)] 
  dat$cumpro=cumproprobit 
  dat$celpro=cell_pro 
  #View(dat) 
  fi=seq(1,(nu_trt*c-c+1), by=c) 
  y=rep(0,nu_trt*c) 
  for(i in fi ){ 
    #rmultinom(1, size = 110, prob = dat$celpro[i:(i+4)]) 
    #checkcell[i:(i+4)]=dat$celpro[i:(i+4)] 
    y[i:(i+4)]= rmultinom(1, size = size, prob = dat$celpro[i:(i+4)]) 
  } 
  dat$y=y 
  #View(dat) 
  #write.csv(dat, "ordinalsimulation2.csv", col.names = TRUE, row.names = FALSE) 
  #size = 20# 
  #ya=rep(0,size*nu_trt) 
  trt_t=rep(0,size*nu_trt) 
  #m=c(1,11) 
  xt=1 
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  #i=11 
  severity <- c(1,2,3,4,5) 
  trt=dat$y[1:c] 
  con=dat$y[(c+1):(c*nu_trt)] 
  yb <- factor(c(rep(severity, con), 
                 rep(severity, trt)), levels = severity) 
   
  trt_t[xt:(xt+(size-1))]=1 
  trt_t[((xt+(size-1))+1):(((xt+(size-1))+1)+(size-1))]=0 
  newdata=data.frame(trt_t,yb) 
  #View(newdata) 
  y=factor(newdata$yb) 
  trt=newdata$trt_t 
  # blk=newdata$blk 
  ## Cumulative link mixed model with two random terms: 
  #probit.m <- clmm(y ~ trt + (1|blk),  link = "probit",threshold = "equidistant") 
  probit.mm <- clm(y ~ trt,  link = "logit") 
  #summary(probit.mm) 
  #n1=10000 
  #b_log=tail(coef(probit.mm),n=1) 
 # y1=rlogis(n1, location = b_log, scale = 1) 
 # y2=rlogis(n1, location = 0, scale = 1) 
  #2*mean(y1>y2)-1 
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 # betap=tail(coef(probit.mm),n=1) 
  #alpha=pnorm(betap/sqrt(2),0,1) 
  #MF=2*alpha-1 
  #print(MF) 
  ###probit model confidence interval 
  #library(bootstrap) 
  #library(boot) 
  theta.hat=function(d,i) 
  { 
    yn<<-factor(d$yb[i]) 
    xn<<-d$trt_t[i] 
    probit.m <- clm(yn ~ xn ,  link = "logit") 
    betap=tail(coef(probit.m),n=1) 
    n1=10000 
    y1=rlogis(n1, location = betap, scale = 1) 
    y2=rlogis(n1, location = 0, scale = 1) 
    MF=2*mean(y1>y2)-1 
  } 
  oboot=boot(data=newdata,statistic=theta.hat, R=5000) 
  BCa.probit=boot.ci(oboot,conf=.95,type="bca") 
  simCI.probit[k,]=BCa.probit$bca[4:5] 
  if(true>=simCI.probit[k,1] && true<=simCI.probit[k,2]){ 
    count.probit=count.probit+1} 
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  average_MF_over_5000.probit[k]=oboot$t0 
















treatment = rep( c(rep("trt", times = c), rep("con", times = c))) 
dat = data.frame(treatment) 
#View(dat) 
for(j in 1:(nu_trt*c)){ 




#cumproplogit = plogis(log_odds) 
mcell_pro=mcumproprobit 
for(j in 2:(nu_trt*c)){ 












for(j in 1:length(p)){ 
  for(k in 1:length(v)){ 
    if(j==k){ 
      alpha=alpha+0.5*p[j]*v[k] 
    } 
    else if(j>k){ 
      alpha=alpha+p[j]*v[k] 
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    } 




















for(k in 1:simN){ 
  ###probit model confidence interval 
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  for(j in 1:(nu_trt*c)){ 
    log_odds[j] =  alpha1[j]-b1*(dat$treatment[j] == "con")    
  } 
  cumproprobit=pnorm(log_odds) 
  #cumproplogit = plogis(log_odds) 
  cell_pro=cumproprobit 
  for(j in 2:(nu_trt*c)){ 
    cell_pro[j]=cumproprobit[j]-cumproprobit[j-1] 
  } 
  cell_pro[seq(1,nu_trt*c,by=c)]=cumproprobit[seq(1,nu_trt*c,by=c)] 
  dat$cumpro=cumproprobit 
  dat$celpro=cell_pro 
  #View(dat) 
  fi=seq(1,(nu_trt*c-c+1), by=c) 
  y=rep(0,nu_trt*c) 
  for(i in fi ){ 
    #rmultinom(1, size = 110, prob = dat$celpro[i:(i+4)]) 
    #checkcell[i:(i+4)]=dat$celpro[i:(i+4)] 
    y[i:(i+4)]= rmultinom(1, size = size, prob = dat$celpro[i:(i+4)]) 
  } 
  dat$y=y 
  #View(dat) 
  #write.csv(dat, "ordinalsimulation2.csv", col.names = TRUE, row.names = FALSE) 
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  #size = 20# 
  #ya=rep(0,size*nu_trt) 
  trt_t=rep(0,size*nu_trt) 
  #m=c(1,11) 
  xt=1 
  #i=11 
  severity <- c(1,2,3,4,5) 
  trt=dat$y[1:c] 
  con=dat$y[(c+1):(c*nu_trt)] 
  yb <- factor(c(rep(severity, con), 
                 rep(severity, trt)), levels = severity) 
   
  trt_t[xt:(xt+(size-1))]=1 
  trt_t[((xt+(size-1))+1):(((xt+(size-1))+1)+(size-1))]=0 
  newdata=data.frame(trt_t,yb) 
  #View(newdata) 
  y=factor(newdata$yb) 
  trt=newdata$trt_t 
  # blk=newdata$blk 
  ## Cumulative link mixed model with two random terms: 
  #probit.m <- clmm(y ~ trt + (1|blk),  link = "probit",threshold = "equidistant") 
  probit.mm <- clm(y ~ trt,  link = "probit") 
  summary(probit.mm) 
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  betap=tail(coef(probit.mm),n=1) 
  alpha=pnorm(betap/sqrt(2),0,1) 
  MF=2*alpha-1 















treatment = rep( c(rep("trt", times = c), rep("con", times = c))) 
dat = data.frame(treatment) 
#View(dat) 
for(j in 1:(nu_trt*c)){ 




#cumproplogit = plogis(log_odds) 
mcell_pro=mcumproprobit 
for(j in 2:(nu_trt*c)){ 












for(j in 1:length(p)){ 
  for(k in 1:length(v)){ 
    if(j==k){ 
      alpha=alpha+0.5*p[j]*v[k] 
    } 
    else if(j>k){ 
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      alpha=alpha+p[j]*v[k] 
    } 









for(k in 1:simN){ 
  ###probit model confidence interval 
  for(j in 1:(nu_trt*c)){ 
    log_odds[j] =  alpha1[j]-b1*(dat$treatment[j] == "con")    
  } 
  cumproprobit=plogis(log_odds) 
  #cumproplogit = plogis(log_odds) 
  cell_pro=cumproprobit 
  for(j in 2:(nu_trt*c)){ 
    cell_pro[j]=cumproprobit[j]-cumproprobit[j-1] 
  } 
  cell_pro[seq(1,nu_trt*c,by=c)]=cumproprobit[seq(1,nu_trt*c,by=c)] 
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  dat$cumpro=cumproprobit 
  dat$celpro=cell_pro 
  #View(dat) 
  fi=seq(1,(nu_trt*c-c+1), by=c) 
  y=rep(0,nu_trt*c) 
  for(i in fi ){ 
    #rmultinom(1, size = 110, prob = dat$celpro[i:(i+4)]) 
    #checkcell[i:(i+4)]=dat$celpro[i:(i+4)] 
    y[i:(i+4)]= rmultinom(1, size = size, prob = dat$celpro[i:(i+4)]) 
  } 
  dat$y=y 
  #View(dat) 
  #write.csv(dat, "ordinalsimulation2.csv", col.names = TRUE, row.names = FALSE) 
  #size = 20# 
  #ya=rep(0,size*nu_trt) 
  trt_t=rep(0,size*nu_trt) 
  #m=c(1,11) 
  xt=1 
  #i=11 
  severity <- c(1,2,3,4,5) 
  trt=dat$y[1:c] 
  con=dat$y[(c+1):(c*nu_trt)] 
  yb <- factor(c(rep(severity, con), 
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                 rep(severity, trt)), levels = severity) 
  trt_t[xt:(xt+(size-1))]=1 
  trt_t[((xt+(size-1))+1):(((xt+(size-1))+1)+(size-1))]=0 
  newdata=data.frame(trt_t,yb) 
  #View(newdata)   
  y=factor(newdata$yb) 
  trt=newdata$trt_t 
  # blk=newdata$blk 
  ## Cumulative link mixed model with two random terms: 
  #probit.m <- clmm(y ~ trt + (1|blk),  link = "probit",threshold = "equidistant") 
  probit.m <- clm(y ~ trt,  link = "logit") 
  betap=tail(coef(probit.m),n=1) 
  n1=10000 
  y1=rlogis(n1, location = betap, scale = 1) 
  y2=rlogis(n1, location = 0, scale = 1) 
  MF=2*mean(y1>y2)-1 
  average_MF_over_5000.logit[k]=MF} 
